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ABSTRACT
Two-arm group sequential designs have been widely used for over forty years, es-
pecially for studies with mortality endpoints. The natural generalization of such
designs to trials with multiple treatment arms and a common control (MAMS de-
signs) has, however, been implemented rarely. While the statistical methodology for
this extension is clear, the main limitation has been an efficient way to perform the
computations. Past efforts were hampered by algorithms that were computationally
explosive. With the increasing interest in adaptive designs, platform designs, and
other innovative designs that involve multiple comparisons over multiple stages, the
importance of MAMS designs is growing rapidly. This dissertation proposes a group
sequential approach to design MAMS trial where the test statistic is the maximum
of the cumulative score statistics for each pair-wise comparison, and is evaluated at
each analysis time point with respect to efficacy and futility stopping boundaries
while maintaining strong control of the family wise error rate (FWER).
In this dissertation we start with a break-through algorithm that will enable us
to compute MAMS boundaries rapidly. This algorithm will make MAMS design a
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practical reality. For designs with efficacy-only boundaries, the computational effort
increases linearly with number of arms and number of stages. For designs with both
efficacy and futility boundaries the computational effort doubles with successive in-
creases in number of stages. Previous attempts to obtain MAMS boundaries were
confined to smaller problems because their computational effort grew exponentially
with number of arms and number of stages.
We will next extend our proposed group sequential MAMS design to permit adap-
tive changes such as dropping treatment arms and increasing the sample size at each
interim analysis time point. In order to control the FWER in the presence of these
adaptations the early stopping boundaries must be re-computed by invoking the con-
ditional error rate principle and the closed testing principle. This adaptive MAMS
design is immensely useful in phase 2 and phase 3 settings.
An alternative to the group sequential approach for MAMS design is the p-value
combination approach. This approach has been in place for the last fifteen years.This
alternative MAMS approach is based on combining independent p-values from the
incremental data of each stage. Strong control of the FWER for this alternative ap-
proach is achieved by closed testing. We will compare the operating characteristics
of the two approaches both analytically and empirically via simulation. In this dis-
sertation we will demonstrate that the MAMS group sequential approach dominates
the traditional p-value combination approach in terms of statistical power.
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1Chapter 1
Introduction
1.1 Introduction
Recent advances in medical science have greatly widened our knowledge in many
disease areas. This has increased the prospect of availability of more effective and
safer drugs for patients. Even with so many advances in medical science only 10% of
all drugs started in human clinical trials ever become an approved drug. One reason
can be the increasing cost in bringing a drug from laboratory to market by conducting
clinical trials. In 2014, Tufts Center for the Study of Drug Development reported that
a drug maker spent around $ 2.55 billion to bring a drug to the market. Out of this,
$1.46 billion was spent for the clinical study purpose only. These huge costs limit
the number of treatments that can be evaluated at one time for a particular disease.
Therefore it eventually discourages investigators from considering multiple possible
treatments for a single disease. Of late there has been real interest in assessing several
treatments for a single disease in one trial. This has got the potential to increase the
efficiency of drug development process and therefore any contribution in this effort
will be of a great practical interest.
The methodology of two-arm group sequential trials is well established and widely
implemented in clinical trial settings. These types of designs allow comparing a single
treatment against a control group in a sequential manner with several interim anal-
yses. Interim analyses allow stopping early either due to futility or due to sufficient
proof of efficacy. Thus, these designs are useful in preventing unnecessary exposure
2of patients to an unsafe new drug or to a placebo treatment if the new drug is already
showing a significant improvement. Since, in the terminology of the Food and Drug
Agency’s Guidance on Adaptive Design (2010, page 18), group sequential methods
are ”well understood”, they are frequently adopted for confirmatory phase 3 clinical
trials, especially in diseases with mortality endpoints. A very good reference to the
literature on group sequential methods can be found in the textbooks by Jennison
& Turnbul (1999), and Proschan, Lan & Wittes (2006). A natural extension of this
methodology is to conduct a group sequential trial to compare multiple treatments
against a common control in a pairwise manner. This is commonly known as multi-
arm multi-stage (MAMS) design and some recent trials on cancer therapy such as
ICON5 (Bookman et al. (2009)), FOCUS4 (Richman et al. (2015)) and STAMPEDE
(Sydes et al. (2009)) have used this type of design. In the MAMS design, several treat-
ments are simultaneously assessed against a common control group, within a single
randomized trial. MAMS design provides several advantages over running separate
controlled trials for each experimental treatment:
• A single shared control group can be used to assess all the treatments, rather
than a separate control group to asses each treatment. Use of a common placebo
group reduces the total number of patients required to assess all the treatments.
• The use of interim analyses allows ineffective treatments to be dropped early
due to futility, or early stopping of the trial if one treatment is clearly superior.
Consequently this results in the reduction of the time and expense to find at
least one effective treatment from a set of several new treatments.
Despite the above mentioned benefits of increased efficiency, this type of design brings
about several challenges including the issue of multiplicity. A family (or a set) of
hypotheses will have to be tested due to the fact of assessing multiple treatments
simultaneously. Because of that, controlling the type-I error in this case is more
3complicated than in traditional two-arm design. The type-I error is called family
wise error rate (FWER) in this case and is defined as the probability of rejecting
any true null hypothesis. Strong control of FWER means the probability of rejecting
any true null hypothesis is controlled at a prespecified level and it is mandatory for
a confirmatory trial to get a drug approval from regulatory agencies like Food and
Drug Agency(FDA), European Medical Agency (EMA) etc. The multi-arm multi-
stage design that we will propose in this thesis will maintain strong control over
FWER and we will prove that this is so analytically as well by simulations.
1.2 Previous Researches on Multiple Arms Multiple Stages
Design
One of the early approaches to deal with pairwise multi-arm comparison is due to
Dunnett (1955), but it is restricted to a single stage only. Suppose there are several
treatments to be compared against a common control in a single randomized trial.
Dunnett’s test computes Student’s t-statistic for each treatment by comparing against
the control group. By using the same control group in all the comparisons, this
procedure incorporates correlation between any two t-statistics. The formal test
statistic in Dunnett’s test is the maximum of these t-statistics and the critical values
are computed using the distribution of the maximum statistic. A table with critical
values was published by Dunnett in 1960 which made it possible to compare up to 20
arms to a common control. Extensions of Dunnett’s approach to multi-stage design
came much later.
For the very first time Follmann, Proschan & Geller (1994) tabulated boundaries
for Pocock and O’Brien-Fleming’s tests in a trial with up to five arms and up to
six stages. Their computations were based on 100,000 simulated multivariate nor-
mals and they assumed an equal variance and balanced randomization. Because of
4the computational difficulty involved, the authors also considered a much simpler
Bonferroni correction. Although Bonferroni correction is more conservative than the
Dunnett correction, it was observed that the increase in critical values for multi-
arm analogues of the Pocock, O’Brien and Fleming tests was small, particularly for
smaller number of comparative arms. Furthermore, a Bonferroni correction permits
greater flexibility by allowing different boundaries to be used for different arms, such
as a Pocock boundary for one arm and an O’Brien and Fleming type of boundary
for another. In their design, treatment arms were dropped from the trial if they were
significantly inferior to control at the interim analysis. To increase power, the au-
thors propose a sequentially rejective Bonferroni procedure in which boundaries are
relaxed for remaining arms if other treatments are dropped during the course of the
trial due to futility. For example consider we start the trial with D treatment arms
but at the interim we drop some treatments and only S treatments are selected. In
this case, after interim a two-arm group sequential procedure with significance level α
S
may be used to assess each of the remaining treatments without inflating the FWER.
But as noted by Magirr, Jaki & Whitehead (2012) this method is too conservative,
particularly, in situations where there is a pressing need to find at least one effec-
tive treatment and only limited resources are available. Under that scenario designs
that allow arms to be dropped using some prespecified criteria are likely to be more
appealing.
One such design, proposed by Stallard & Todd (2003), selects the most promising
of several treatments at the end of the first stage. Thereafter the selected treatment
will be compared against the placebo for the remainder of the trial. This design uses
the efficient score statistic to make test decisions and is applicable to trials with either
binary, time to event or normally distributed outcomes. It also allowed the selected
treatments to be compared with the control at a number of interim analyses after
5the first stage. But prespecified selection criteria of selecting the most promising
treatment was the biggest drawback of this design. Importantly, the most promising
treatment need not always be selected at the end of the first stage and other outcomes
such as safety could play a role in the decision making process. In such a scenario,
the test will be conservative as the type I error rate will be smaller than the desired
significance level. Many a time it may be required to continue with more than one
arm beyond the first stage.
In practice, the constraint of allowing only one arm to continue beyond the first
interim analysis is likely to be too restrictive. The design by Stallard & Todd (2003)
can be generalized further by allowing any number of treatment arms to continue
beyond first stage. Stallard & Friede (2008) proposed such a design, where FWER
gets controlled in strong sense provided that the number of arms to be selected after
the first stage are prespecified, regardless of which arms are actually continued during
the course of the trial. They achieved this by considering the sum of the largest
increments in the score statistics of all selected arms at each stage (after the first
stage ) and constructing stopping boundaries using an alpha-spending function based
on this sum of maximum incremental statistics. Since the largest score statistic for an
individual arm will be no higher than this maximal sum, the test is conservative under
the global null hypothesis. This design is useful for multi-arm multi-stage design in
the the context of treatment selection design. But one limitation of this proposed
design is that once the trial has started, it must be conducted as specified and select
the prespecified number of arms after the first stage.
Later Magirr, Jaki & Whitehead (2012) proposed a more flexible multi-arm multi-
stage design for normally distributed outcomes. Their design generalized the Dunnett
test to a multi-stage trial and stopping boundaries were derived in such a way that
the FWER was controlled in the strong sense. Their designs incorporated binding
6futility boundaries which can be used to drop treatments at interim. Computation of
the stopping boundaries uses the distribution of maximum of the Wald statistics and
it involved numerical integration which can be computationally intensive particularly
for designs with a large number of arms and stages.
A design for monitoring multiple treatments that provides the practical flexibility
of nonbinding futility boundaries while controlling the FWER in the strong sense
was proposed by Chen, DeMets & Lan (2010). This was achieved by deriving the
efficacy boundary under the assumption of no stopping for futility. Adding a stopping
boundary for futility therefore decreases the type I error rate below its nominal level;
however, trade off is that arms do not necessarily have to be dropped for futility if
they fall below this boundary.
1.3 Objective of this Thesis
The biggest computation burden for MAMS design, is associated with the construc-
tion of early stopping boundaries whilst preserving the FWER. All these approaches
made in the past in computing group sequential boundaries for multi-arm multi stage
design have not so far been entirely successful. Stallard & Friede (2008), Chen,
DeMets & Lan (2010) and Magirr, Jaki & Whitehead (2012) all have difficulty in
computing these boundaries for larger, still realistic, problem. This is primarily be-
cause the computational problem has not been handled satisfactorily. Key part in
computing boundaries for a two-arm design, was the use of the recursive formula by
Armitage, McPherson & Rowe (1969). All the methods proposed so far for multi-arm
multi-stage design utilized the Wald statistics, which does not exhibit independent
increment structure needed to apply the recursive formula. Although the design pro-
posed by Stallard & Todd (2003) and Stallard & Friede (2008) did use the score
statistics, they have not used the independent incremental property of score after
7performing treatment selection at first stage. In Chapter 2 of this thesis we propose
an efficient algorithm that computes the group sequential boundaries of a MAMS de-
sign using score statistics. As is well known score statistics is a Brownian process that
follows a multivariate normal distribution, when the mean of the responses are known.
Also the independent increment property allows us to use the recursive formula. On
the other hand considerable research has been devoted on reliable and highly accurate
numerical algorithms for computing multivariate normal probabilities. Genz & Bretz
(1995) summarize this development nicely in their book. Our algorithm combines
these two ideas to develop an efficient algorithm for computing boundaries in MAMS
design. Chapter 2 of this thesis will propose a multi-arm multi-stage design and we
will come up with an efficient algorithm to compute the group sequential boundaries.
In addition, power of the design can be computed analytically for a given sample size.
In Chapter 3 of this thesis we will see dropping arm(s) at interim can easily
be incorporated in our proposed design without having to make any change to the
future stage boundaries. But the trial will be under-powered and readjustment of
the boundaries for the rest of the trial will be needed to recover the power. The
updated boundaries should be computed in such a way that FWER will not be in-
flated (this is an important consideration because the strong control of FWER is a
mandatory requirement from FDA’s perspective). We will apply the conditional error
rate principle and the closed testing principle to incorporate adaptive changes in our
proposed MAMS design. Use of these two principles will guarantee a strong con-
trol over FWER. In this context we should note that Koenig et al. (2008) proposed
an adaptive Dunnett test in a two stage setting, which combines the closed testing
principle and conditional error rate principle. In their design they compared the in-
cremental stage 2 Dunnett p-value against the conditional error function evaluated at
stage 1. But in our adaptive MAMS Group Sequential design we will re-compute the
8stage 2 boundary using the conditional error rate function. Then we should compare
the stage 2 statistics against the updated boundary. Chapter 3 extends the regular
MAMS Group Sequential design to adaptive MAMS Group Sequential design that
will allow dropping arm(s) or sample size modification during the course of the trial.
In the adaptive MAMS Group Sequential design, boundary re-computation using con-
ditional error rate function requires to be done in simulation level and the efficient
algorithm from Chapter 2 allows the simulations to be done in real time.
An alternate method for designing a multi-arm multi-stage trial is based on the
p-value combination test. This approach relies on the application of the closed test-
ing principle along with combining p-values with prespecified combination function.
The closed testing principle according to Marcus, Peritz & Gabriel (1976) offers a
strong control over FWER when multiple hypotheses are being tested. Due to test-
ing multiple comparators against the placebo, this fits well into our problem. This
design is based on combining independent p-values obtained from each stage by using
a prespecified combination (Fisher, inverse-normal etc.) functions. This strategy was
initially proposed by Bauer & Ko¨hne (1994) where the focus was on two-stage designs
and Fisher’s combination test. Later on extension to multi-stage design was proposed
by Posch et al. (2005) where adaptive treatment selection as well sample size modifi-
cation at interim was possible and therefore is a powerful supplement to our problem.
Since then this approach has been commonly used for adaptive treatment selection
design. In Chapter 4 we compare our proposed adaptive MAMS Group Sequential
design with the P-value Combination design. Comparison done in this research is
mainly based on the study power in a two-stage design. We will compare the powers
from these two approaches under different assumptions about the treatment effects.
Analytical power computation is possible when no adaptive changes are made to the
trial. When adaptive changes are made to the trial, study power can only be com-
9puted using simulations under both the approaches. We will end with a discussion
and future research ideas in this context.
The contents of Chapter 2 in this thesis has already appeared in Biometrics (see
Ghosh et al. (2017)). Contents of Chapter 3 and Chapter 4 are in the process of
submission for publication. Each chapter in this dissertation is meant to be read with
minimal reference to other chapters. Therefore some repetition is unavoidable and
intentional. This is purely to facilitate clarity in reading and flow of the material.
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Chapter 2
Designing Multiple Arms Multiple Stages
Trial
2.1 Introduction
Group sequential design and monitoring of randomized clinical trials has played an
important role in clinical drug development for over forty years. The literature on
group sequential methods is vast and has been presented in a unified manner in
outstanding textbooks by Jennison & Turnbul (1999) and Proschan, Lan & Wittes
(2006). Throughout its forty-year history, the development and use of group sequen-
tial methodology has been largely confined to two-arm trials, in which a proposed
new medical intervention is compared to a standard-of-care control arm with respect
to a single primary endpoint. There is increasing interest, however, in extending the
methodology to multiple pair-wise comparisons to a common control – the so-called
multi-arm multi-stage (MAMS) case. Parmar, Carpenter & Sydes (2014) have argued
persuasively that multi-arm trials allow more treatments to be assessed in less time
than could ever be done in a series of two-arm trials. Equally important, for pa-
tients and policy makers, a multi-arm trial produces contemporaneous results for all
research treatments. Wason & Jaki (2012) compared the sample size requirements of
separate two-arm trials to those of multi-arm trials for Alzheimer’s disease treatments
and showed savings of up to 50%.
A major hurdle to adopting MAMS designs routinely is the computational effort
11
of obtaining stopping boundaries that guarantee strong control of type-1 error. This
problem has not, so far, been handled satisfactorily. Attempts were made by, among
others, Hughes (1993), Follmann et al. (1994), Stallard & Todd (2003), Chen, DeMets
& Lan (2010) and Magirr, Jaki & Whitehead (2012) with varying degrees of success,
as we discuss in Section 2.5. MAMS designs face two major computational hurdles
– unless their special structure is exploited, the computational complexity grows ex-
ponentially with number of arms as well as with number of stages. In all previous
work on MAMS designs, the fact that the independent increments property, so suc-
cessfully exploited for 2-arm trials (see, for example, Armitage et al. (1969)), could be
generalized to the multi-arm setting was never recognized. Additionally, multi-arm
designs involve multivariate normal integration for which special techniques were de-
veloped only in the 1990s (see, for example, Genz & Bretz (1995)), and hence were
not available to the early proponents of MAMS designs.
In this chapter of the thesis we present an algorithm that exploits independent
increments and also utilizes the quasi-Monte Carlo methods of Genz & Bretz (1995,
page 91) to perform multivariate normal integration efficiently. As a result the com-
putational effort required to create designs with efficacy-only boundaries is linear in
both number of arms and number of stages, while the computational effort required
to create designs with both efficacy and futility boundaries remains linear in number
of arms but doubles with each successive increase in number of stages. Furthermore,
because we utilize quasi-Monte Carlo methods, the error in the numerical integra-
tion can be quantified and the accuracy of the resulting stopping boundaries can
be bounded to any desired level of confidence. This is not possible with the other
methods discussed above since they utilize numerical quadrature in their algorithms.
We formulate the problem in Section 2.2 and standardize it in Section 2.3 so as
to eliminate dependence on the variance-covariance matrix of the test statistic. The
12
numerical algorithm is presented in Section 2.4. Sections 2.5 and 2.6 discuss how
the method compares with alternative methods that have been developed for MAMS
designs.The method is applied, for illustrative purposes, to a multi-arm clinical trial
of chronic obstructive pulmonary disease in Section 2.7. We end in Section 2.8 with
some concluding remarks.
2.2 Problem Formulation
2.2.1 Stopping Boundaries for Normally Distributed Data
Consider a group sequential clinical trial in which D treatment arms, indexed by
i = 1, 2, . . .D, are compared in a pairwise manner to a common control arm, indexed
by i = 0. The trial comprises up to J looks at accumulating data, indexed by
j = 1, 2, . . . J . As subjects enter the trial they are randomized to either the ith
treatment arm or the control arm in accordance with a prespecified allocation ratio
of λi. Let Xij ∼ N(µi, σ2i ) denote the response of the ith subject who is enrolled
between look j− 1 and look j. Let δi = µi−µ0. We shall be interested in testing the
global null hypothesis H0: δi = 0 for all i = 1, 2, . . .D against the one-side alternative
hypothesis H1: δi > 0 for at least one i, through a group sequential hypothesis test
strategy that ensures strong control of type-1 error. To that end let ni1 < ni2 · · · < niJ
be the cumulative sample sizes on arm i, xij be the sample mean for the nij subjects
on arm i and δˆij = xij −x0j be the maximum likelihood estimate of δi at look j. The
Fisher information for δi at look j, denoted by Iij, is estimated by the square inverse
of the standard error of δˆij. Thus it is easy to show that Iij = n0jΛi where
Λi =
(
σ20 +
σ2i
λi
)−1
.
Denote the efficient score statistic by Wij = δˆijIij and let W j = (W1j ,W2j , . . .WDj).
Then W j, j = 1, 2, . . . J , is a multivariate Brownian process with the following prop-
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erties:
E(Wij) = δiIij ,
var(Wij) = Iij ,
cov(Wij1 ,Wij2) = Iij1 if j2 > j1 , (2.2.1)
cov(Wi1j ,Wi2j) = Λi1Λi2σ
2
0n0j if i1 6= i2 .
Property (2.2.1) implies that the W j process has independent increments; that is,
Wj1 and Wj2 −Wj1 are independent.
Let δ = (δ1, δ2, . . . δD) and max{W j} = maxi(Wij, i = 1, 2, . . .D). A J-look level-
α group sequential design with early stopping only for efficacy involves evaluation of
efficacy boundaries b1, b2, . . . bJ that satisfy
J∑
j=1
P0(
j−1⋂
l=1
max{W l} < bl ∩max{W j} ≥ bj) = α (2.2.2)
where Ph(.) denotes probability under δ = h. These efficacy boundaries are typically
computed recursively. The overall type-1 error α is first split into J positive com-
ponents (α1, α2, . . . αJ) in accordance with some prespecified error spending function
(Lan and DeMets, 1983) such that
∑
j αj = α. Now suppose that b1, . . . bj−1 have
already been evaluated. Then bj is obtained from the jth term in equation (2.2.2) by
solving
P0(
j−1⋂
l=1
max{W l} < bl ∩max{W j} ≥ bj) = αj . (2.2.3)
Notice that these efficacy boundaries have been evaluated under the complete null
hypothesis δ = 0. It can be shown, however, that because they utilize max{W j} at
each look, they do provide strong control of type-1 error (see Magirr et al. (2012)).
Once the efficacy boundaries have been evaluated one can compute β, the type-2
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error of the design at any alternative hypothesis, say δ = δ1, as
β = Pδ1(
J⋂
j=1
max{W j} < bj) . (2.2.4)
One can also incorporate futility boundaries, (a1, a2, . . . aJ−1, aJ = bJ), into the design
such that the trial may be stopped for futility if max{W j} ≤ aj for any j, in which
case the type-2 error is
β =
J∑
j=1
Pδ1(
j−1⋂
l=1
al < max{W l} < bl ∩max{W j} ≤ aj) . (2.2.5)
In practice the futility boundaries are made non-binding by first evaluating the ef-
ficacy boundaries b1, b2, . . . bJ . Next an arbitrary value is selected for β, the type-2
error for any pre-specified sample size, and is split into J components (β1, β2, . . . βJ),∑J
j=1 βj = β, in accordance with some desired error spending function. Now suppose
that a1, . . . , aj−1 have already been evaluated. Then at look j, aj can be evaluated
by equating the jth term in equation (2.2.4) with βj. Thus
Pδ1(
j−1⋂
l=1
al < max{W l} < bl ∩max{W j} ≤ aj) = βj . (2.2.6)
This entire procedure is iterated with different values of β until the aJ = bJ ; that is,
the boundaries must meet at the last look. The final value of β thus evaluated will
be the actual type-2 error of the study.
We show in Appendix 1 that the probability equations (2.2.3) and (2.2.6) can be
solved by repeated evaluation of “component probabilities” of the form
Pδ(
j⋂
l=1
max{W l} < cl) (2.2.7)
where cj is either aj or bj , depending on the context. We also show in Appendix 1
that at any look j it is necessary to evaluate 2j such individual components, each
15
being of order j ×D.
2.2.2 Generalization to Discrete and Time-to-Event Models
Although the above formulation for designing a multi-arm multi-stage group se-
quential design assumes that the underlying data are normally distributed, it is
applicable more generally to clinical trials with continuous endpoints, binary end-
points, time-to-event endpoints and even to regression models in which the test
statistics are derived as efficient scores from the likelihood function, by a straight-
forward application of methods by Jennison & Turnbull (1997) (JT) for two-arm
group group sequential designs. The basic result is Theorem 2 of JT which states
that for general parametric regression models in which δ denotes the coefficients of
the covariates and cTδ is any linear contrast, the sequentially computed score statis-
tics W j = {var(cTδˆj)}−1(cTδˆj − cTδ), j = 1, 2, . . . J , are multivariate normal with
independent increments. Theorem 3 of JT presents a analogous result for the Cox
proportional hazard model in which δ is a vector of log hazard ratios. These results
form the basis of most major software packages for group sequential inference with
normal, binomial and time to event endpoints. The EastR© software package provides
simulation tools to verify the accuracy of the results or make appropriate adjustments
for small sample sizes.
2.2.3 Repeated Confidence Intervals
The repeated confidence intervals proposed by Jennison & Turnbull (1989) for two
arm designs extend naturally to MAMS designs. Consider a D-arm, J-look MAMS
design with level-α efficacy boundaries bj , j = 1, 2, . . . J computed as discussed above.
These boundaries must satisfy the relationship
P0(
J⋂
j=1
max{W j} < bj) = 1− α ,
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which, under Hh: δ = h, is equivalent to
Ph(
J⋂
j=1
max
i=1,...D
{Wij − hiIij} < bj) = 1− α .
In other words, the event {Wij − hiiij < bj , i = 1, . . .D, j = 1, . . . J} occurs with
probability 1− α. Since Wij = δˆijIij , it follows that for every comparison i at every
look j the event {δˆijIij−hiIij < bj} occurs with probability at least 1−α whereupon
the 1 − α lower repeated confidence bound for hi is δˆij − bj/Iij. By a symmetrical
argument the upper repeated confidence bound is δˆij + bj/Iij .
2.3 Standardized Score Statistics
In order to evaluate component probabilities of the form (2.2.7) it is desirable to
transformW j such that the sample size affects the transformed statistic only through
its mean and not through its covariance matrix, for then the efficacy boundaries will
not depend on sample size. Accordingly we define a new stochastic process
U j =
W j√Imax
, j = 1, 2, . . . J, (2.3.8)
where Imax = maxi{IiJ , i = 1, 2, . . .D} is the maximum information at the final look,
over all the δi parameters. Let tj = n0j/n0J , Λmax = maxi{Λi, i = 1, 2, . . .D}, and
define the “drift parameter” for treatment i by
ηi = δi
(
Λi
Λmax
)√
Imax = δi
(
Λi
Λmax
)√
n0JΛmax .
Then U j is a multivariate brownian process of independent increments with:
E(Uij) = tjηi ,
var(Uij) = tj
(
Λi
Λmax
)
,
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cov(Uij1 , Uij2) = tj1
(
Λi
Λmax
)
if j2 > j1 ,
cov(Ui1j, Ui2j) = tjσ
2
0
(
Λi1Λi2
Λmax
)
if i1 6= i2 .
Define the D ×D matrix ρ by
ρlm =
{
σ20
(
ΛlΛm
Λmax
)
if l 6= m
Λl
Λmax
if l = m .
Let η = (η1, η2, . . . ηD) and t = (t1, t2, . . . tj). Then U j ∼ N(tjη, tjρ) with independent
increments. Equation (2.2.7) is thus transformed into
P(∩jl=1max{U l} < dl|t, η,ρ) (2.3.9)
where dl = cl/
√Imax. We will develop an efficient numerical algorithm for evaluat-
ing (2.3.9).
2.4 Numerical Algorithm
2.4.1 Integration over a Unit Hypercube
The independent increment structure of U j enables us to factor (2.3.9) into a product
of nested integrals that can be solved recursively. To see this observe that
P (∩jl=1max{U l} < dl|t, η,ρ) = P (U1 < d1, U2 < d2 . . . U j < dj|t, η,ρ)
=
∮
u1<d1
∮
u2<d2
· · ·
∮
uj<dj
f(u1, u2, . . . uj |t, η,ρ)du1du2 . . . duj
(2.4.10)
where f(u1, u2, . . . uj |t, η,ρ) is the joint density of (U 1, U 2, . . . U j) and ul < dl means
that uil < dl for all i = 1, 2, . . .D. Factoring f(.) as a product of conditional proba-
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bilities we can re-write (2.4.10) as
∮
u1<d1
∮
u2<d2
· · ·
∮
uj<dj
f(u1; t, η,ρ)f(u2|u1; t, η,ρ) . . . f(uj |uj−1, . . . u1; t, η,ρ)du1du2 . . . duj .
(2.4.11)
where U1 ∼ N(t1η, t1ρ). Define U (l) = U l − U l−1, l > 1. Then U (l) is independent
of U l−1, U l−2, . . . U 1 and has a multivariate normal distribution with mean t(l)η and
variance matrix t(l)ρ, where t(l) = tl − tl−1. We may now re-write (2.4.11) as a
recursive multivariate integral of a product of densities of independent increments of
the form∮
u1<d1
∮
u(2)<d2−u1
· · ·
∮
u(j)<dj−uj−1
f(u1; t1η, t1ρ)f(u(2); t(2)η, t(2)ρ) . . .f(u(j); t(j)η, t(j)ρ)
du(1)du(2) . . . du(j)
or more conveniently as
∮
u1<d1
f1(u1)du1
∮
u(2)<d2−u1
f2(u(2))du(2) · · ·
∮
u(j)<dj−uj−1
fj(u(j))du(j) , (2.4.12)
where u(l) < dl − ul−1 means that u(il) < dl − ui,l−1 for all i = 1, 2, . . .D, and
fl(u(l)) =
1
(2π)D/2
√
det(t(l)ρ)
exp
{
−1
2
(
u(l) − t(l)η√
t(l)
)′
ρ−1
(
u(l) − t(l)η√
t(l)
)}
.
The next step is to replace (2.4.12) with a product of univariate integrals. To this
end let ρ = CC ′ be the Choleskey decomposition of ρ where C is a lower triangular
matrix. Using the linear transformation (u(l) − t(l)η)/
√
tl = Cyl, l = 1, 2, . . . j,
as discussed in Genz & Bretz (1995, page 29), we have u′(l)ρ
−1u(l) = y
′
l
yl and the
Jacobian of the transformation is given by
J ≡ ∂u1, u(2), . . . u(j)
∂y
1
, y
2
, . . . y
j
=
√
tlC .
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Therefore det(J) = det(
√
t(l)C) =
√
det(t(l)ρ) and the product of the j multivariate
normal integrals (2.4.12) can be rewritten as a product of D × j univariate normal
integrals
g11∫
−∞
φ(y11) dy11 · · ·
gD1∫
−∞
φ(yD1) dyD1 · · ·
g1l∫
−∞
φ(y1l) dy1l · · ·
gDl∫
−∞
φ(yDl) dyDl · · ·
g1j∫
−∞
φ(y1j) dy1j · · ·
gDj∫
−∞
φ(yDj) dyDj
(2.4.13)
where the limits of integration are shown in Appendix 2 of the Supplementary Mate-
rials to be
gil =
1
Cii
[
1√
t(l)
(
dl − tlηi −
i∑
m=1
Cim
l−1∑
k=1
ymk
√
t(k)
)
−
i−1∑
m=1
Cimyml
]
(2.4.14)
for i = 1, 2, . . .D, l = 1, 2, . . . j, and a summation is null if its lower limit exceeds its
upper limit. We utilize the transformation Φ(yil) = zil to convert (2.4.13) to the form
e11∫
0
dz11 · · ·
eD1∫
0
dzD1 · · ·
e1l∫
0
dz1l · · ·
eDl∫
0
dzDl · · ·
e1j∫
0
dz1j · · ·
eDj∫
0
dzDj , (2.4.15)
where
eil = Φ
{
1
Cii
[
1√
t(l)
(
dl − tlηi −
i∑
m=1
Cim
l−1∑
k=1
Φ−1(zmk)
√
t(k)
)
−
i−1∑
m=1
CimΦ
−1(zml)
]}
(2.4.16)
for i = 1, 2, . . .D, l = 1, 2, . . . j.We implement a final transformation zil = eilxil for
i = 1, 2, . . .D, l = 1, 2, . . . j. Then (2.4.15) is converted to the form
1∫
0
e11dx11 · · ·
1∫
0
eD1dxD1 · · ·
1∫
0
e1ldx1l · · ·
1∫
0
eDldxDl · · ·
1∫
0
e1jdx1j · · ·
1∫
0
eDjdxDj
(2.4.17)
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for integration over the unit hypercube [0, 1]D×j, and eil is re-expressed as
eil = Φ
{
1
Cii
[
1√
t(l)
(
dl − tlηi −
i∑
m=1
CimQm,l−1
)
−
i−1∑
m=1
CimΦ
−1(emlxml)
]}
(2.4.18)
to show explicit dependence of eil only on eml, m = 1, 2, . . . i − 1, and on Qm,l−1 =∑l−1
k=1Φ
−1(emkxmk)
√
t(k), m = 1, 2, . . . i. This relationship shows that although (2.4.17)
appears to be a product of independent integrals on the unit hypercube, the inte-
grands, eij , are linked recursively. Note, for future reference, the recursion
Qml = Qm,l−1 + Φ
−1(em,lxm,l)
√
t(l), for l = 2, . . . j .
We shall evaluate (2.4.17) by quasi-Monte Carlo integration.
2.4.2 Quasi-Monte Carlo Integration
Denote the multiple integral (2.4.17) by
I =
1∫
0
· · ·
1∫
0
f(x)dx11 . . . dxDj . (2.4.19)
where x = (x11, x21, . . . xD1, . . . x1j , x2j , . . . xDj) and f(x) =
∏j
l=1
∏D
i=1 eil. The inte-
grand e(x) is computed by evaluating each eil recursively as described below.
Look 1 At look l = 1, each ei1, i = 1, 2, . . .D, is evaluated as a function of the
preceding em1, m = 1, 2, . . . i− 1, according to the formula
ei1 = Φ
{
1
Cii
[
1√
t1
(d1 − t1ηi)−
i−1∑
m=1
CimΦ
−1(emlxml)
]}
.
Finally the terms Qi1 = Φ
−1(ei1xi1)
√
t1, i = 1, 2, . . .D, are saved for use at look
l = 2.
Look 2 At look l = 2, each ei2, i = 1, 2, . . .D, is evaluated as a function of the
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preceding em2, m = 1, 2, . . . i− 1, and by the Qi1, i = 1, 2, . . .D that were saved
at look l = 1, according to the formula
ei2 = Φ
{
1
Cii
[
1√
t(2)
(
d2 − t2ηi −
i∑
m=1
CimQm1
)
−
i−1∑
m=1
CimΦ
−1(em2xm2)
]}
.
Finally the terms Qi2 = Φ
−1(ei2xi2)
√
t2 + Qi1, i = 1, 2, . . .D, are saved for use
at look l = 3.
Look l At any general look l each eil, i = 1, 2, . . .D, is evaluated as a function of
the preceding eml, m = 1, 2, . . . i− 1, and by the Qi,l−1, i = 1, 2, . . .D that were
saved at look l − 1, according to the formula
eil = Φ
{
1
Cii
[
1√
t(l)
(
dl − tlηi −
i∑
m=1
CimQm,l−1
)
−
i−1∑
m=1
CimΦ
−1(emlxml)
]}
.
Finally the terms Qil = Φ
−1(eilxil)
√
tl +Qi,1−1, i = 1, 2, . . .D, are saved for use
at look l + 1.
These computations proceed look by look for l = 1, 2, . . . j and f(x) is finally eval-
uated as the product of the individual eil terms. Let xl = (x1l, x2l, . . . xDl), Ql =
(Q1l, Q2l, . . . QDl), and el = e1le2l · · · dDl Then the above computations imply that
f(x) = e1(x1)e2(x2, Q1) · · · ej(xj, Qj−1) .
One can obtain a crude Monte Carlo estimate for I by sampling x uniformly from a
D × j dimensional unit hypercube. Let x(1),x(2), . . .x(N) be the N sampled values.
Then
IN =
1
N
N∑
n=1
f(x(n)) (2.4.20)
is an unbiased estimate of I with standard error of order O(N−1/2). It is possible
to improve the accuracy of the crude Monte Carlo estimate by a quasi-Monte Carlo
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(QMC) procedure that combines the above randomly generated points with a fixed
sequence of points created by lattice rules. We shall use a QMC procedure proposed
by Genz & Bretz (1995, page 47-48). A rank-1 lattice is a point set of the form
LP = { iυP
P
mod 1, i = 1, 2, . . . P}
where P is a prime number and (in our setting) υP is a D×j dimensional vector that
depends on P . Many choices have been proposed for (P,υP ). In order to achieve
O(N−1+ǫ) integration errors, good lattice parameters must be determined. Genz
(2000, http://www.math.wsu.edu/faculty/genz/software/fort77/mvnpack.f )
has created a table of (P,υP ) combinations based on the component by component
algorithms of Dick & Kuo (2004), and Nuyens & Cools (2006) that are well suited to
multivariate normal integration. Our computations utilize (P, υP ) values from this
table, a subset of which is displayed in Figure C·1 of the Supplementary Materials.
The QMC procedure is outlined below.
1. Select a (P,υP ) combination and construct the lattice LP consisting of P points
each of dimension D × j.
2. For each lattice point zp ∈ LP generateM random vectors ∆p,m ∼ U [0, 1]D×j, m =
1, 2, . . .M .
3. For a given m let
IP,m =
1
2P
P∑
p=1
(f(|2{zp +∆p,m} − 1|) + f(1− |2{zp +∆p,m} − 1|))
where {a} = a mod 1. Then a QMC estimate of I is given by
IP,M =
1
M
M∑
m=1
IP,m
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with variance
σ2P,M =
1
M(M − 1)
M∑
m=1
(IP,m − IP,M)2 .
4. Further variance reduction is achieved by repeating steps 1 to 3 with additional
(P,υP ) combinations. Suppose we utilize K rank-1 lattices, generated by com-
binations (Pk,υPk) and resulting in the estimates IPk,M , k = 1, 2, . . .K. Then
the final estimate of I, due to LePage (1978), is
I = σ2
K∑
k=1
IPk,M
σ2Pk ,M
with standard error
σ =
(
K∑
k=1
1
σ2Pk ,M
)−1/2
.
2.4.3 Accuracy
Standard error estimates of the crude Monte Carlo (MC) and quasi-Monte Carlo
(QMC) procedures are displayed in Table 2.1 for various choices of D and J . The
MC estimates are displayed for 50,000 independent samples. The QMC estimates are
displayed for M = 6 and a suitable value of K such that
∑K
k=1 Pk ≈ 50, 000. Thus,
for the comparison of the two procedures with respect to accuracy, the number of
sampled points is approximately the same.
These results ensure that the 99.9% confidence interval for I based on QMC
will be at least as accurate as I ± 0.001 even for a design with 5 comparisons to a
common control and 5 looks at accumulating data. Larger problems are unlikely to
be encountered in the clinical trials setting.
24
Table 2.1: Accuracy Comparison of Crude and Quasi-Monte Carlo
Integration
Looks Comparisons Standard Error of Integral Estimate
(J) (D) QMC Integration MC Integration
2 0.000075 0.029537
3 0.000156 0.016844
2 4 0.000302 0.027771
5 0.000421 0.029855
2 0.000359 0.041026
3 0.000495 0.029950
3 4 0.000502 0.031194
5 0.000637 0.035716
2 0.000566 0.040911
3 0.000591 0.043898
4 4 0.000595 0.047661
5 0.00062 0.048621
2 0.000739 0.050674
5 3 0.001083 0.047483
4 0.001324 0.049185
5 0.000995 0.041286
Based on 50,000 MC and approximately 50,000 QMC simulations
2.4.4 A Non-Technical Explanation of Quasi-Monte Carlo
Multivariate normal probability computations typically involve semi-definite inte-
gration. For one-dimensional problems semi-definite integration is performed by
quadrature methods. A multi-dimensional integral can be expressed as repeated one-
dimensional integrals by applying Fubini’s theorem. But the computational effort of
using numerical quadrature grows exponentially with the number of dimensions. To
avoid that, one usually considers Monte Carlo methods for multi-dimensional inte-
gration.
The Monte Carlo method requires the multivariate integral to be a definite in-
tegral. The transformations in Section 2.4.1 convert the semi-definite multivariate
normal integral (2.4.10) into a definite integral over a hypercube. The regular Monte
Carlo method averages the repeated evaluations of the integrand function over a
random sequence of grid points. However, as we demonstrated in Table 2.1, us-
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ing random sequences in this way is not sufficiently efficient for MAMS boundary
computations. This led us to the quasi-Monte Carlo integration described in Sec-
tion 2.4.2. In quasi-Monte Carlo integration some points are chosen deterministically
using low-discrepancy measures to make the computations converge faster. These
low-discrepancy points are combined in a specific way with random sequences of
points so as to make the computation robust. The creation of these sequences of low-
discrepancy points utilize number theory methods that are outside the scope of this
thesis. In particular we have used the Korovob (1960) sequence of low-discrepancy
points, and the Matsumoto & Nishimura (1998) method for combining them with
random sequences.
2.5 Comparison with Alternative Algorithms
The most recent published method for generating stopping boundaries and computing
sample size for MAMS designs is by Magirr, Jaki & Whitehead (2012). An R program
implementing this method and maintained by Jaki is available at
https://cran.r-project.org/web/packages/MAMS/index.html
Tables 2.2 and 2.3 compare the execution times of the new algorithm described in
Section 2.4, hereafter referred to as NEW, and the R implementation of the Magirr,
Jaki & Whitehead (2012) method, hereafter referred to as MJW, for a range of treat-
ment comparisons and looks at the accruing data. All computations were executed
on a Lenovo Think Pad, Model T440P with Intel i7 processor and 8 core CPUs.
Table 2.2 displays results for designs with efficacy-only boundaries while Table 2.3
displays results for both efficacy and futility boundaries.
It is evident from these tables that, for designs with efficacy-only boundaries, the
computing times of NEW are linear in both D and J , while they increase as 2J for
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Table 2.2: Execution Time Comparison of QMC and MJW Methods
for MAMS Designs with Efficacy Boundary Only
Looks Comparisons Execution Times (secs)
(J) (D) NEW MJW
2 1 2
3 1 2
2 4 2 2
5 2 2
2 1 138
3 1 148
3 4 1 148
5 2 158
2 1 > 28,800
3 1 > 28,800
4 4 2 > 28,800
5 2 > 28,800
2 1 > 28,800
3 2 > 28,800
5 4 2 > 28,800
5 2 > 28,800
Total Sample Size is 600 for all Designs
Table 2.3: Execution Time Comparison of QMC and MJW Methods
for MAMS Designs with Efficacy and Futility Boundaries
Looks Comparisons Execution Times (secs)
(J) (D) NEW MJW
2 2 2.5
3 3 2.5
2 4 4 3
5 4 3
2 5 138
3 11 142
3 4 13 157
5 18 170
2 16 > 28,800
3 21 > 28,800
4 4 32 > 28,800
5 35 > 28,800
2 30 > 28,800
3 43 > 28,800
5 4 62 > 28,800
5 93 > 28,800
Total Sample Size is 600 for all Designs
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designs with both efficacy and futility boundaries. In contrast the execution times of
the MJW algorithm increase exponentially with J for designs with or without futility
boundaries and break down entirely for J > 3.
It is insightful to analyze why MJW, unlike NEW, is computationally explosive
as the number of stages increase. Both algorithms must compute the probability of
the very same event
R(δ) =
D⋂
i=1
(
J⋃
j=1
[{
j−1⋂
i=1
lj < Tij < uj
}])
(2.5.21)
for a normally distributed statistic Tij and suitably standardized efficacy and futility
boundaries lj and uj. The difference is that MJW uses the Wald statistic δˆi
√
Iij
for Tij , whereas NEW uses the score statistic δˆiIij for Tij , for computing the event
(2.5.21). This initial choice of test statistic dooms the MJW method for it can
no longer utilize the underlying stage-wise independent increments structure of the
problem. Instead the problem gets transformed into the form
∞∫
−∞
· · ·
∞∫
−∞
D∏
i=1
[
J∑
j=1
Φj{Lij , U ij}
]
dΦ(t1) · · · dΦ(tJ) (2.5.22)
where, for the ith treatment comparison, Φj{Lij , U ij} denotes the result of integrating
the j-dimensional multivariate normal density over a region defined by a vector of
lower limits Lij and a vector of upper limits U ij. Decomposition of (2.5.22) into a
product of univariate normal integrals such as we have obtained in (2.4.17) is clearly
impossible. Evaluation of (2.5.22) is by numerical quadrature. Suppose each of the J
dimensions of the outer integral
∫∞
−∞
· · · ∫∞
−∞
(· · · ) dΦ(t1) · · ·dΦ(tJ) is divided into G
grid points. For each grid point the inner product-sum
∏D
i=1
[∑J
j=1Φj{Lij, U ij}
]
is
evaluated by repeated calls to a function such as mvtnorm (Genz et al 2016). For each
i = 1, 2, . . .D, there are j, repeated calls to mvtnorm, in which each call evaluates a
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region {Lij, U ij} of a j-dimensional multivariate normal density. This computation
must be repeated for j = 1, 2, . . . J . It follows that the MJW algorithm must make∑J
j=1G
D×j calls to mvtnorm to evaluate (2.5.22). Assuming that G = 20, the current
implementation of MJW in R, one can see why the problem breaks down entirely for
J > 3, even for the balanced case where only
∑J
j=1G
j calls to mvtnorm are needed.
In contrast the NEW algorithm, by exploiting the independent increments struc-
ture of Wij , is able to transform the problem into a simple product of univariate
integrals of the form (2.4.17) from which the stopping boundaries, type-1 error or
power can be obtained by a recursive computation that is linear in D or J when only
efficacy boundaries are evaluated, and linear in D but increasing like 2J when both
efficacy and futility boundaries are evaluated.
Prior to MJW, methods to obtain group sequential boundaries for MAMS designs
were proposed by Hughes (1993), Follmann, Proschan & Geller (1994), Stallard &
Todd (2003) and Chen, DeMets & Lan (2010). All these methods utilized the Wald
statistic for the computations and so suffer from the same limitation as MJW. Hughes
(1993) simply utilizes the boundaries of a two-arm clinical trial, relying on binding
futility rules established via simulation, for dropping non-performing arms in mid-
course, and thereby preserving the type-1 error conservatively. There is no guarantee
that this approach will provide strong control of type-1 error. Follmann et al. (1994)
start out by computing Bonferroni based stopping boundaries and then adjusting
them by simulation. This approach is satisfactory for pre-computing and tabulating
stopping boundaries for specific α values, number of arms and number of looks. It
may not be as satisfactory when boundaries have to be re-computed via α-spending at
interim analyses that do not adhere to the pre-specified design parameters. Stallard
& Todd (2003) propose to select the dose with the maximum Wald statistic at the
first interim analysis and drop the other doses, so that the remainder of the trial
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utilizes conventional two-arm boundaries. The option to carry more than one dose
forward is not provided. Chen, DeMets & Lan (2010) utilize numerical quadrature
when J ×D ≤ 6 and recommend simulation when J ×D is more than 6 .
2.6 Comparison with Combination P-value Methods
An alternative method to test multiple treatment arms against a common control arm
with possible treatment selection at one or more interim analysis time points, is by
combining p-values from the different stages with pre-specified weights and and using
a closed test for the final analysis. Since the p-values from the separate stages are inde-
pendent and uniformly distributed under the null hypothesis (or stochastically larger
than uniform in the discrete case), their combination with pre-specified weights is also
uniformly distributed so that valid level-α tests may be constructed. In this approach
p-values are required both to test elementary hypotheses of the form Hj: δj = 0 as
well as intersection hypotheses of the form Hi ∩ Hj ∩ Hk: δi = δj = δk = 0. The
latter p-values are adjusted for multiplicity by methods proposed by, among others,
Dunnett, Bonferroni and Simes. An excellent reference to the combination p-value
method is the paper by Posch et al. (2005).
Although the MAMS and combination p-value approaches tackle essentially the
same problem the two approaches are fundamentally different. MAMS, having its
roots in Markov processes, exploits the known correlation structure of the sequentially
computed score statistic when computing the early stopping boundaries. The p-value
combination approach on the other hand, having its roots in multiple comparisons
methodology, exploits closed testing (Marcus, Peritz & Gabriel (1976)) to control the
type-1 error. Moreover since, in this approach the independent incremental data
from each stage are combined, correlations between sequentially computed cumula-
tive statistics across stages are not exploited. It would thus be of interest to make
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power comparisons between the two methods. There are actually three definitions of
power in a multi-arm setting; global power, disjunctive power, and conjunctive power.
Global power is the probability that at least one treatment arm will attain statistical
significance. Disjunctive power is the probability that at least one non-null treatment
arm will attain statistical significance. Conjunctive power is the probability that all
non-null treatment arms will attain statistical significance.
Table 2.4 displays disjunctive and conjunctive power comparisons between the
MAMS method and three commonly used combination p-value methods – Bonfer-
roni, Simes and Dunnett. These power comparisons are for 3, 4, and 5-arm designs
with three equally spaced looks, 50 subjects per arm, the Lan and DeMets (1987),
O’Brien-Fleming (1979) type boundary for early efficacy stopping, δ/σ = 0.5 for each
treatment arms relative to the control arm, and a futility rule that drops any treat-
ment arm if its estimated δˆ < 0 at an interim look. All table entries are based on
100,000 simulations.
Table 2.4: Power Comparisons of P-value Combination and MAMS
Procedures (all entries based on 100,000 simulations)
Disjunctive Power
Arms Bonferroni Simes Dunnett MAMS
3 0.717 0.732 0.732 0.766
4 0.722 0.735 0.746 0.805
5 0.726 0.736 0.750 0.835
Conjunctive Power
Arms Bonferroni Simes Dunnett MAMS
3 0.380 0.395 0.381 0.428
4 0.247 0.263 0.256 0.294
5 0.174 0.193 0.185 0.208
The MAMS designs dominate over all the combination p-value designs. Bonferroni is
less powerful than Simes, which in turn in less powerful than Dunnett. Furthermore,
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as shown in Section 2.2.3 the MAMS approach can provide repeated confidence inter-
vals that guarantee coverage of each δ at each look, albeit conservatively. Confidence
intervals for treatment effects are not yet available by p-value combination methods.
We will do a more detailed comparison between these two approaches in the presence
of adaptive changes to the trial in Chapter 4 of this thesis.
2.7 The INHANCE Clinical Trial of COPD
Indacaterol to Help Achieve New COPD Treatment Excellence (INHANCE) was a
randomized clinical trial for the treatment of chronic obstructive pulmonary disease
in which four doses (75mg, 150 mg, 300 mg, 500 mg) of inhaled indacaterol, a once-
daily long-acting β2-agonist bronchodilator were compared to placebo (Donohue et
al, 2010). The primary efficacy objective was to show the superiority of at least
one dose over placebo at week 12 with respect to 24-hour post-dose (trough) forced
expiratory volume in 1 second (FEV1). The improvement in FEV1 for indacaterol
versus placebo, denoted by δ, was expected to be between 0.14 and 0.18 liters and the
between-subject variability was assumed to be σ = 0.5. Although the actual trial had
only two-stages and utilized closed testing for preserving the type-1 error (Donohue et
al. (2010)), we will use this setting to illustrate a MAMS design comprising three pair-
wise comparisons (150 mg, 300 mg, 500 mg) to placebo over up to four equally-spaced
looks at the accumulating data. The design will utilize the Lan & DeMets (1983) error
spending function to generate (O’Brien & Fleming, 1979) type boundaries (LD(OF)
boundaries) to generate early stopping efficacy boundaries. Table 2.5 displays these
boundaries on the Wald scale and contrasts them with corresponding boundaries for
a conventional four-look group sequential design (GSD) with only one treatment arm
versus placebo.
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Table 2.5: Comparison of 2-arm and 4-arm LD(OF) Boundaries (1-
sided α = 0.025)
Information Wald Scale Boundaries
Look Fraction 2-arm 4-arm
1 0.25 4.3326 4.5654
2 0.5 2.9631 3.2655
3 0.75 2.359 2.7225
4 1.00 2.0141 2.4142
The 4-arm boundaries are stricter than the 2-arm ones because, with three com-
parisons to placebo, there are three times as many chances for declaring efficacy under
the global null hypothesis in the MAMS design compared to the 2-arm GSD.
Suppose we wish the COPD trial to have 90% global power under the alternative
hypothesis H1: δ1 = 0.14, δ2 = 0.16, δ3 = 0.18. We will adopt the LD(OF) boundaries
for early efficacy stopping with type-1 error = 0.025 to reject the global null hypothesis
H1: δ1 = δ2 = δ3 = 0. These efficacy boundaries will preserve the type-1 error
conservatively if treatment arms are dropped in mid-stream for any reason, including
excess toxicity. It is nevertheless desirable to incorporate formal futility boundaries
into the design so as to have objective criteria for dropping non-performing arms at
one or more interim analysis time points. Table 2.6 displays the maximum sample
size, expected sample size under H1 and expected sample size under H0 for designs
with between 1 and 4 looks, LD(OF) efficacy boundaries and non-binding LD(OF)
futility boundaries.
Table 2.6: Sample Size Requirements for COPD Trial with 1 to 4
Looks
Number of Sample Sizes for 90% Power
Looks Maximum Under H1 Under H0
1 624 624 624
2 644 558 446
3 668 522 420
4 684 502 401
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There are large savings in expected sample size, with diminishing returns as the
number of looks increase. The efficacy and futility boundaries for the 4-look design
are displayed on the Wald scale in Figure 2·1.
Figure 2·1: Efficacy and Futility Boundaries
2.8 Discussion
We have shown how one may create MAMS designs efficiently, illustrated their ap-
plication to trials involving multiple doses, and found them to have greater power
than competing designs based on combining p-values from independent stages. On
the face of it the computational problem appears intractable. If one attempts to solve
it by numerical quadrature as was attempted by Magirr, Jaki and Whitehead (2012)
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(MJW), the complexity increases exponentially with number of looks and breaks
down entirely for designs with more than 3 looks at the accumulating data. Our ma-
jor contribution was to show that if the problem is viewed in the proper framework it
can be transformed such that the computational complexity is linear in both number
of looks and number of arms for designs with efficacy-only boundaries and doubles
with successive stages for designs with both efficacy and futility boundaries. Thus,
for example, designs with six arms (including the control arm) and five stages can
be created in under two minutes by the NEW algorithm. This type of performance
frees the trial designer to experiment with different design options including number
of looks, types of stopping boundaries and sample size, under alternative scenarios for
the treatment effects. This is a crucially important consideration for optimizing trial
design. If one had to wait several hours or days in between scenarios it is unlikely
that one would consider more than one or two design options and might miss out on
the best possible design for the situation under consideration.
The full potential of our algorithm has not yet been realized. We have seen from
Table 2.2, that once the design has more than one interim analysis the computational
effort of the MJW algorithm can increase by two orders of magnitude. For example,
a 3-look design with efficacy-only boundaries involving 3 comparisons to a common
control takes 1 second with the NEW algorithm but 148 seconds with the MJW al-
gorithm. While 148 seconds might not be a limitation for one-time computation of
early-stopping boundaries, it can be an impassable barrier for evaluating the operat-
ing characteristics of more sophisticated MAMS designs. Increasingly there is interest
in efficient adaptive designs where dose are dropped, the sample size is re-estimated,
and the stopping boundaries are re-computed at interim looks (see (Magirr et al.,
2012); Gao et al. (2014)). In such designs the type-1 error is preserved by matching
the conditional error rates of the original and adapted designs as was done for the
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INHANCE trial in Section 2.7. The operating characteristics of such designs can only
be evaluated by simulation experiments in which the early stopping boundaries are
repeatedly re-computed on-the-fly. The evaluation of even a single scenario involving
10,000 simulations (the bare minimum for a realistic evaluation of operating charac-
teristics in an actual clinical trial) would become impractical for a design with three
or more looks if it required 148 seconds per simulation. With the NEW algorithm,
however, it was computationally feasible to run as many as 100,000 simulations per
design and we will see in Chapter 3 of this thesis.
Recently there has been much discussion about so called “platform trials” in
which several promising treatment regimens from different companies are tested on
a common platform. In such trials multiple arm are monitored in group sequential
fashion. Losing arms are dropped and replaced by new arms. Strong control of type-1
error is a regulatory requirement of such studies. The STAMPEDE trial (Sydes et al.
(2009)) is one such trial. We are currently working on various examples of adaptive
designs that will exploit the full power of our algorithm and will present these results
in subsequent papers.
We end on a note of caution. As stated in Section 2.2.2, the early stopping bound-
aries are based on the asymptotic normality of the score statistic. We have found, by
simulating t-statistics 100,000 times with 200 subjects/arm, that the actual type-1
error of a design with nominal 1-sided α = 0.025 is 0.026, regardless of the number
of stages. With 400 subjects/arm, however, the actual type-1 error is preserved at
0.025 or less. This suggests that at the design stage of a confirmatory clinical trial
one must verify through extensive simulation what nominal type-1 error will guaran-
tee that the 1-sided actual type-1 error remains below 0.025. A systematic study of
the rate of convergence to normality of the various test statistics commonly used for
normal, binomial and time-to-event data would be desirable, and is made possible by
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the ready availability of the relevant stopping boundaries through the present work.
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Chapter 3
Adaptive Multiple Arms Multiple Stages
Trial
3.1 Introduction
Multi-arm multi-stage (MAMS) adaptive clinical trials compare multiple treatment
arms in pair-wise fashion to a common control arm over two or more stages. These
trials are characterized by interim looks at the accumulating data in order to stop
the trial early for overwhelming efficacy, drop ineffective treatment arms, make mid-
course changes to the sample size, change the error spending function, or change the
number of future looks. The MAMS Group Sequential approach generalizes the usual
two-arm group sequential design (for example, Jennison & Turnbul (1999)) to the
multi-arm setting. A separate cumulative score statistic is obtained for each pair wise
comparison to a common control arm. Early stopping boundaries are derived from the
distribution of the maximum of the score statistics under the global null hypothesis
that all treatment arms are ineffective. These boundaries provide strong control of
the family wise error rate (FWER). Boundaries for the special case in which only
control arm and the treatment arm with the largest test statistic at the end of stage 1
are selected for further investigation were developed by Stallard & Todd (2003). More
recently Magirr, Jaki & Whitehead (2012) developed a general approach in which the
maximum of the Wald statistics is used to compute the group sequential boundaries
over multiple stages. Chapter 2 of this thesis reduced the computational complexity
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of this approach by using the maximum score statistic, in place of the maximum Wald
statistic. This chapter we show how to extend the MAMS Group Sequential design
so as to permit adaptive changes such as dropping treatment arms and altering the
sample size at one or more stages. FWER control is maintained by invoking the
Mu¨ller and Scha¨fer conditional error rate principle and the closed testing principle to
re-compute the group sequential boundaries. In Section 3.2 we introduce the Group
Sequential design and show how the group sequential boundaries are computed using
distribution of the maximum score statistic. In Section 3.3 we incorporate adaptive
treatment selection and sample size re-estimation into the design. In Section 3.3.1
we explain the strong control of FWER by using closed testing principle along with
conditional error rate principle after making adaptive changes. We further explored
the advantages of this adaptive MAMS design using some simulation experiments.
We end this chapter with some conclusion. Although we are confining the discussion
to designs with two stages, this is for ease of exposition only. The methods presented
here extend directly to more than two stages.
3.2 Multiple Arms Two Stages Design
Consider a trial in which there are D treatment arms, indexed by i = 1, 2, . . .D.
Each treatment arm will be assessed against a common control arm, indexed by
i = 0. Patients are randomized between the control or one of the treatment arms, i,
in accordance with some pre-specified allocation ratio of λi. We assume the response
of patients on arm i, i = 0, 1, 2, . . .D, follows a normal distribution with mean µi
and variance σ2i . Suppose δi = µi − µ0 represents the treatment effect of arm i for
i = 1, 2, . . .D. We consider a two stage design, indexed by j, where j = 1 stands for
the interim look and j = 2 is the final look. For treatment arm i the null hypothesis
is H i0 : δi = 0. The global null hypothesis is the intersection of all the H
i
0’s and is
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denoted by H0 : δi = 0 for all i = 1, 2, . . .D. We will test H0 against the alternative
H1 : δi > 0 for at least one i. In the following we will use the first subscript to stand
for arm and the second subscript for stage. Suppose Wij =
(
X¯ij − X¯0j
) Iij represents
the score statistic for arm i at stage j, for i = 1, 2, . . .D and j = 1, 2. Here X¯ij is the
sample mean of arm i, i = 0, 1, 2, . . .D, based on all data up to and including stage
j. Also Iij is the Fisher information about δi at stage j. Then Iij = n0jΛi, where n0j
is the cumulative number of patients on the control arm up to and including stage
j and Λi =
(
σ20 +
σ2i
λi
)−1
. The score statistic W j = (W1j ,W2j, ...WDj) at stage j is a
multivariate Brownian process with following properties:
E(Wij) = δiIij
V ar(Wij) = Iij
Cov(Wi1,Wi2) = Ii1
Cov(Wi1j,Wi2j) = Λi1Λi2σ
2
0n0j ; if i1 6= i2.
The structure of Cov(Wi1,Wi2) implies that W j has independent increments. That
is, W 1 and W (2) ≡ (W1(2),W2(2), · · ·WD(2)) = W 2 − W 1 are independent. Clearly
W (2) also follows a multivariate normal distribution with:
E(Wi(2)) = δiIi(2)
V ar(Wi(2)) = Ii(2)
Cov(Wi1(2),Wi2(2)) = Λi1Λi2σ
2
0n0(2); if i1 6= i2.
Here n0(2) = n02 − n01 and Ii(2) = n0(2)Λi is the Fisher information about δi based
on the incremental data between first and second stages. Let δ = (δ1, δ2, ...δD) and
max{W j} = maxi(Wij ; i = 1, 2, ...D) represent maximum score statistic by stage j.
Suppose out of a total type I error α, we are allowed to spend only α1 at the interim.
Then the group sequential boundaries b1, b2 of a two look level α test should satisfy
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the following criteria:
P0 (max{W 1} ≥ b1) = α1
P0 (max{W 1} < b1 ∩max{W 2} ≥ b2) = α− α1, (3.2.1)
where Ph(.) denotes the probability under δ = h. Due to the use of the maximum
of score statistics, these boundaries maintain strong control of FWER (Magirr et
al. (2012)). In Chapter 2 of this theis we had already shown how to compute these
boundaries for the general case of any number of looks. Suppose at the end of the first
stage w1 = (w11, w21, . . . wD1) is the observed value of the score statistic. If for any
i = 1, 2, . . .D, wi1 ≥ b1, then the corresponding null hypothesis H i0 can be rejected.
Rejection of any elementary null hypothesis H i0 implies rejection of the global null
hypothesis H0. If no treatment arm crosses the efficacy boundary at the first stage,
the trial may either be terminated for futility or proceed to the second stage with
possible adaptive changes.
3.3 Adaptive Group Sequential Design
If no arm crosses the efficacy boundary at stage 1, and the trial is not terminated
for futility, then it continues to stage 2 with possible treatment selection and possible
sample size modification. At the end of stage 1, arms that appear to be ineffective or
unsafe may be dropped from further consideration. Patients entering the study during
stage 2 will then randomize patients to the remaining arms including the control arm.
As a consequence, the stage 2 sample size must be adjusted. There are three options:
(a) Reduce the total sample size such that the stage 2 sample sizes for the selected
arms are the same as they would have been in the original design.
(b) Maintain the originally planned total sample size and increase the sample sizes
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of the selected arms for stage 2 by corresponding amounts.
(c) Increase the originally planned total sample size and allocate the additional
subjects to the selected arms for stage 2. This option will be applicable when
it is desired to boost the condition power for achieving statistical significance
at stage 2, analogous to the promising zone design of Mehta & Pocock (2011).
In all three options the allocation ratio λi of each treatment i to control remains un-
changed. Under option (a) strong control of the FWER can be maintained without
adjusting the second stage boundary b2 as computed in equation (3.2.1). It is desir-
able, however, to adjust b2 by an adaptive method as this will increase the overall
power of the trial. Under options (b) and (c) strong control of FWER can only be
achieved by an adaptive adjustment of b2. The adaptive adjustment of b2 utilizes
the conditional error rate principle (Mu¨ller & Scha¨fer (2001)) along with the closed
testing principle (Marcus et al. (1976)). This is discussed next.
3.3.1 Conditional Error Rate and Closed Testing
Let D = {1, 2, ...D} and S ⊆ D denote the indices of the treatments carried over to
stage 2. At stage 2 we are interested in testing H i0 for all i ∈ S while maintaining
strong control of the FWER at level α. To achieve this control, eachH i0 must be tested
by a closed level-α test. That is, H i0 may only be rejected if, for all I ⊆ D such that
i ∈ I, HI0 = ∩q∈IHq0 is rejected with a valid local level-α test. In order to construct
a valid local level-α test of HI0 we utilize the Mu¨ller and Scha¨fer principle (2001)
of preserving the conditional type-1 error under HI0 , before and after an adaptive
change. For the set I, let W Ij = {Wqj; q ∈ I} ⊆ W j be the score statistic at look j
and max{W Ij} = maxq(Wqj ; q ∈ I) be the maximum of the components in W Ij.
Level-α boundaries (bI1, bI2) corresponding to H
I
0 must satisfy:
P0 (max{W I1} ≥ bI1) = α1
42
P0 (max{W I1} < bI1 ∩max{W I2} ≥ bI2) = α− α1. (3.3.2)
Suppose wI1 is the value of W I1 observed at stage 1. Then the conditional type 1
error, α∗I , due to rejecting H
I
0 when it is true is computed as
α∗I = P0 (max{W I2} ≥ bI2|W I1 = wI1)
= 1− P0 (∩q∈IWq2 < bI2|W I1 = wI1) (3.3.3)
= 1− P0
(∩q∈IWq(2) < bI2 − wq1) . (3.3.4)
Here Wq(2) = Wq2 −Wq1 represents the incremental score statistic for the treatment
q, based on the incremental data between stages 1 and 2 and equation (3.3.4) follows
from (3.3.3) because, as shown in Section 3.2, W (2) has independent increments.
If there is an adaptive change of sample size at the end of stage 1, let n∗0(2) denote
the incremental sample size of the control arm for stage 2, W ∗q2 denote the score
statistic for treatment q based on all the data up to and including stage 2, and W ∗q(2)
denote the score statistic based only on the incremental data for stage 2. Then W ∗q(2)
also follows a multivariate normal distribution with mean and variance
E(W ∗q(2)) = δqI∗q(2)
V ar(W ∗q(2)) = I∗q(2)
Cov(W ∗q1(2),W
∗
q2(2)
) = Λq1Λq2σ
2
0n
∗
0(2).
where I∗q(2) = n∗0(2)Λq is the Fisher information for δq based only on the incremental
observations between stage 1 and stage 2. Let IS = I∩S be the set of treatments from
I that are carried to second stage. Denote the maximum score statistic corresponding
to the set IS at end of stage 2 as max{W ∗IS2} = max(W ∗q2; q ∈ IS). By the conditional
error rate principle of Mu¨ller and Scha¨fer, the new boundary, b∗I2, for testing the null
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hypothesis HI0 must satisfy the requirement
α∗I = P0
(
max{W ∗IS2} ≥ b∗I2|W IS1 = wIS1
)
= 1− P0
(∩q∈ISW ∗q2 < b∗I2|W IS1 = wIS1)
= 1− P0
(∩q∈ISW ∗q(2) < b∗I2 − wi1)
. (3.3.5)
We reject HI0 if the observed value of max{W ∗IS2} exceeds b∗I2. This ensures that HI0
is tested by a valid level-α test. Finally, rejection of H i0 requires that H
I
0 be rejected
in the above manner for all possible subsets I ⊆ D that contain i. This will ensure
that the test of H i0 is closed and will thereby guarantee strong control of FWER.
3.3.2 Why Closed Testing is Necessary
We have stated in Section 3.2 that the group sequential boundaries (b1, b2) that are
obtained under the global null hypothesis δi = 0 for all i = 1, 2, . . .D, provide strong
control of the FWER without the requirement of closed testing. If, however, some
arms get dropped at the interim and, in addition, the sample size is adjusted, we will
need closed testing to achieve strong control of FWER. To show that type-1 error
may be inflated in the absence of closed testing we simulated a four-arm, two-stage
trial having a total sample size of 400, an interim analysis after 200 subjects, and
equal allocation to three treatment arms along with a common control arm. Group
sequential boundaries were obtained for the two stages based on the Lan-DeMets error
spending function with one-sided α = 0.025. The simulations were conducted under
δ1 = 0, δ2 = 0, δ3 = 0.4, and σ = 1. For purposes of this counter-example, we assume
that in each simulation the treatment with the best observed response was dropped
due to excessive toxicity and the treatment with the worst observed response was
dropped due to futility. The remaining treatment arm and the control arm proceeded
to stage 2 and the remaining 200 patients were re-allocated to these two arms.
According to the notation of Section 3.3.1, D = {1, 2, 3}. Let s denote the selected
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treatment for stage 2 and Hs0 be the null hypothesis that δs = 0. In order to test
Hs0 with strong control of FWER, it is necessary to test H
I
0 with a valid local level-
0.025 test for all subsets I ⊆ D that include s. In our first simulation experiment
we performed this test, as described in Section 3.3.1, only for HD0 but not for other
subsets I ⊂ D. Had there been no adaptations, the test of HD0 alone would have
sufficed for strong control of FWER. However, because our simulations incorporated
adaptive treatment selection and sample size modification, the FWER was 0.042,
almost double the nominal α = 0.025. We then performed a second simulation
experiment in which Hs0 was rejected only if H
I
0 was rejected by a local level-0.025
test for all I ⊆ D, s ∈ I. In this experiment, the FWER was controlled and equaled
0.0252. To explain the methodology we will consider the following example.
3.4 Example
Consider a two-stage trial, where three experimental arms will be compared against
a common placebo. Suppose out of total type I error of amount 0.025, 0.00152
will be spent at the stage 1. We consider a total sample size of amount 600 with
an 1:1 randomization between each treatment and control and the interim analysis
takes place after 300 patients. This implies nij = j ∗ 75 for any i = 0, 1, 2, 3 and
j = 1, 2. Suppose we observe W11 = 5.598,W21 = 13.88 and W31 = 2.301 at end of
the stage 1. Furthermore, suppose that the investigators decide to drop treatment
3 from the second stage due to a safety endpoint but continue with treatments 1
and 2. Therefore, according to our notation in this example S = {1, 2} and at the
final analysis we will test only H10 and H
2
0 . By closed testing principle rejecting H
1
0
with strong control of FWER at level α will requires rejection of all HI0 at the same
level where 1 ∈ I. Possible values of I can be {1, 2, 3}, {1, 2}, {1, 3} and {1}. After
dropping the treatment 3 we did not modify the sample size on any other arms. Second
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and third column in Table 3.1 shows the original stage 1 and 2 boundaries for testing
the null hypothesis HI0 at level 0.025. The fourth column represents conditional type I
error corresponding to that HI0 . Updated second stage boundaries (b
∗
I2) are displayed
in the last column. Suppose at the end of stage 2 we observe the value of W12 as
Table 3.1: Original and modified stopping boundaries on Score scale
for 3-arms 2-stages design after dropping the third arm at the interim
Original Conditional Modified
boundaries type I boundary
I Look 1 Look 2 error Look 2
{1, 2, 3} 20.051 20.416 0.1464 20.406
{1, 2} 19.368 19.237 0.1954 19.237
{1, 3} 19.368 19.237 0.0152 18.855
{2, 3} 19.368 19.237 0.1919 19.222
{1} 18.143 17.048 0.0308 17.048
{2} 18.143 17.048 0.3029 17.048
20.409. With this being observed, we can reject all HI0 where 1 ∈ I. But if we did not
update the boundaries and used the original boundary 20.416 we could not reject H10
at the end stage 2. Next we will compare the advantage of adaptive MAMS design,
over non-adaptive MAMS design using simulation.
3.4.1 Simulation Example : INHANCE Trial
We will continue with the same example about INHANCE trial (Donohue et al.
(2010)) from Chapter 2. It was a randomized clinical trial for the treatment of chronic
obstructive pulmonary disease where four doses (75mg, 150 mg, 300 mg, 500 mg) of
inhaled indacaterol were compared against a common placebo in pairwise manner.
The primary efficacy objective was to show the superiority of at least one dose over
placebo at week 12 with respect to 24-hour post-dose (trough) forced expiratory
volume in 1 second (FEV1). The improvement in FEV1 for three dose groups of
indacaterol versus placebo was expected to be between 0.14 and 0.16 and 0.18 liters
and the between-subject variability was assumed to be σ = 0.5. 628 subjects were
required to detect 90% power in a two stage design assuming 1-sided type I error as
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0.025 . Interim analysis was considered after 314 patients. For this experiment, type
I error spent at the interim was computed from the Lan and DeMets error spending
function. We compared powers obtained from four drop-the-loser designs and power
from each design was obtained by running 100,000 simulations. In each simulation we
generated data for each patient from a normal distribution with common standard
deviation (σ) of 0.5 and mean in three dose groups as 0.14, 0.16 and 0.18 . Patient
response in control group was assumed as normal with mean 0 and σ = 0.5. At end of
the stage 1 the best dose group with largest value of estimated treatment effect was
selected for the stage 2. Along with the best dose, we selected all other doses whose
treatment effect that differ from the best dose by less than ǫ. In the first two designs
(second and third column of the table) after dropping doses at the interim we did not
change stage 2 sample size for the selected arms. Therefore, the overall sample size
used in the whole trial were less than 628, the originally planned sample size. In the
first design we had used the original boundary b2 for the stage 2 analysis whereas in the
third design we recomputed the second stage boundary and performed a closed test as
explained in Section 3.3.1. In the third design we maintained the originally planned
sample size (628) for the the whole trial and therefore increased the stage 2 sample
size for the the selected arms in corresponding amounts. Along with dropping doses,
Table 3.2: Comparison of powers obtained from four different adaptive
drop the loser designs
Drop the loser designs
Stage 2 Sample Size(Selected Arms, Total)
Fixed, Reduced Increase, Fixed Increase, Increase
Boundary Boundary
ǫ Not Readjusted Readjusted
0.1 0.9045 0.905 0.924 0.947
0.05 0.8886 0.9049 0.9399 0.962
0.01 0.8574 0.8809 0.9565 0.971
0.005 0.848 0.8754 0.9576 0.978
0.001 0.8443 0.8726 0.9589 0.982
0.0005 0.8439 0.8697 0.96 0.989
we had increased the originally planned total sample size for the trial in the fourth
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design and thereby stage 2 sample sizes for the selected arms were also increased. In
all these four designs randomization ratio between any selected arm and the placebo
in the second stage was maintained to 1:1 as the original design. The criteria to
sample size increase in the last design was based on the standardized treatment effect
of the best dose, estimated at the interim. We had decided if estimated standardized
treatment effect of the best doses lies between 0.2 and 0.3, we will increase the stage 2
sample size by 50% more from 314 to 628. Because there has been an adaptive changes
to the trial for the last two designs we had to readjust the second stage boundary to
control FWER in strong sense. The boundaries for all these designs were computed
assuming σi = 0.5 for each arm i. However, as suggested by Wason et al. (2016),
these boundaries are further transformed by the formula
b∗ij =
√
IˆijT
−1
dij

Φ

 bj√
Iˆij



 (3.4.6)
to adjust for possible biases in small samples due to estimating the unknown σ2i for
each treatment i in the computation of the test statistic. Here
Iˆij = n0j
(
σˆ20j +
σˆ2ij
λi
)−1
is the estimated Fisher information about δi at stage j, σˆ
2
i is the estimated variance
of the response to treatment i, based on cumulative data up to and including stage
j, and T−1dij is the inverse of the student’s t distribution with degrees of freedom
dij = n0j + nij − 1. This adjustment to the boundaries allows us to use estimated
Fisher information in place of the unknown actual Fisher information without inflating
the type-1 error. Table 3.2 compares power obtained from these four drop the loser
designs for different values of ǫ. All the table entries are based on 100,000 simulations.
As the values of ǫ decreases second design have larger advantage over the first design
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Table 3.3: Family wise error rate in adaptive drop the loser designs
Drop the loser designs
Stage 2 Sample Size(Selected Arms, Total)
Fixed, Reduced Increase, Fixed Increase, Increase
Boundary Boundary
ǫ Not Readjusted Readjusted
0.1 0.0241 0.0247 0.0247 0.0247
0.05 0.0245 0.0247 0.0247 0.0248
0.01 0.0238 0.0248 0.0248 0.0249
0.005 0.0236 0.0248 0.0248 0.0248
0.001 0.0232 0.0248 0.0247 0.0251
0.0005 0.0219 0.0247 0.0249 0.0252
because of the adaptive readjustment of stage 2 boundary. In the the third design
we had increased stage 2 sample size of the selected arms to maintain the originally
planned total sample size (628) of trial. This design always has larger power than the
first two designs and that is due to using a larger sample size than the other two. In
the fourth design where the total sample size of the trial was increased has the largest
power among all these designs. Next we simulated the same experiment where the
response data were generated assuming the null hypothesis H0 was true. Response of
each patient in each dose group was generated assuming treatment effect in each dose
group was 0. Table 3.3 displays the results from 100,000 simulations. These results
confirm FWER was controlled in strong sense in all four designs.
3.5 Extension to More than Two Stages Design
So far we have discussed the adaptive multi-arm group sequential design for a two-
stage design only. But the theory can easily be generalized to more than two stages.
In Chapter 2 we have already discussed non-adaptive MAMS design in the context of
any number of stages. Consider a design where D treatments will be assessed against
a common placebo in J stage design. We have already seen the group sequential
boundaries b1, b2, . . . bJ can be computed for this design which will provide a strong
control over FWER. Now, we will prespecified stage l and if the trial did not stop
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by the stage l we will perform an adaptive changes like dropping arms or modifying
sample size as explained through options (a)-(c) in the section 3.3. After these,
suppose S denotes the set of indexes of the selected treatments for analysis in stages
l + 1, . . . J . From stage l + 1 onward we will only test Hq0 such that q ∈ S. By
the closed testing principle a valid level α test for Hq0 will require testing H
I
0 for all
possible subsets I of D that includes q at same level α. As with the case of two stage
design, we will first compute the level α group sequential boundaries bI1, bI2, . . . bIJ
for testing HI0 by solving the following set of equations:
J∑
j=1
P0
(
j−1⋂
k=1
max{W Ik} < bIk
⋂
max{W Ij} ≥ bIj
)
= α.
As explained in Section 2.2 from Chapter 2 these boundaries can be calculated in
recursive way. Then we compute the conditional type I error (α∗I) corresponding to
the hypothesis HI0 using the following equation
α∗I =
J∑
j=l+1
P0
(
j−1⋂
k=l+1
max{W Ik} < bIk
⋂
max{W Ij} ≥ bIj |WIl = wIl
)
= 1− P0
(
J⋂
j=l+1
max{W Ij} < bIj |WIl = wIl
)
= 1− P0
(
J⋂
j=l+1
⋂
q∈I
Wqj < bIj |WIl = wIl
)
Due to adaptive changes at stage l, we will denote the new score statistics for arm
i(i ∈ S) at stage j(j > l) by W ∗j . Then the new score statistic corresponding to I is
W ∗Ij = {Wij ; i ∈ I} and max{W ∗Ij} will denote the maximum of the components in
W ∗Ij. This new test statistic will have the following distribution properties:
E(W ∗ij) = δiI∗ij ,
var(W ∗ij) = I∗ij ,
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cov(W ∗ij1,W
∗
ij2) = I∗ij1 if j2 > j1 > l,
cov(W ∗i1j,W
∗
i2j
) = Λi1Λi2σ
2
0n
∗
0j if i1 6= i2.
Here n∗0j represents the new sample size on placebo arm by stage j after adaptation
and I∗ij = n∗0jΛi denote the new Fisher information at stage j(> l) about δi. We
recompute the new boundaries b∗Il+1, . . . b
∗
IJ for testing H
I
0 by solving the following
equation:
α∗I =
J∑
j=l+1
P0
(
j−1⋂
k=l+1
max{W ∗ISk} < b∗Ik
⋂
max{W Ij} ≥ b∗Ij |WIl = wIl
)
= 1− P0
(
J⋂
j=l+1
⋂
q∈IS
W ∗qj < b
∗
Ij |WIl = wIl
)
.
Here IS = I ∩ S is the set of all treatment indexes from I carried to stage l + 1.
We reject HI0 at stage j > l if the observed value of max{W ∗ISj} exceeds b∗Ij . This
ensures that HI0 is tested by a valid level-α test. Finally, rejection of H
q
0 at stage
j > l requires that HI0 to be rejected in the above manner for all possible subsets
I ⊆ D that contain q at same stage j. This will ensure that the test of Hq0 is closed
and will thereby guarantee strong control of FWER.
3.6 Conclusion
Multi-arm studies with treatment selection are an efficient means for drug develop-
ment when several potentially useful treatments are available for testing. A number
of different studies are now being run under this framework in a variety of disease
areas. Typically, clinical development includes phase 2 and phase 3 trials. A phase 2
trial is generally of exploratory nature, in which several dose groups can be investi-
gated so that the efficacy of the test treatment can be most efficiently demonstrated.
Typically, one of the doses with the most potential to be successful will be selected to
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proceed to a phase 3 trial. The phase 2 trial is thus used for generating hypotheses,
and the objective of the phase 3 trial is to confirm the hypotheses generated form the
phase 2 trial. Sometimes, it is of interest to combine the phase 2 and phase 3 trials
into one seamless trial to save resources and time, thus the drug development can be
more efficient and faster. An adaptive MAMS design discussed in this chapter will
be a very efficient approach to design these types of trial. In this chapter we have
highlighted the potential gains by using adaptive MAMS design. Strong control of
FWER was achieved by using closed test along with conditional error rate principle.
This design does not require the adaptive rules to be prespecified and therefore is
most useful when reacting to unforeseen situations, for example, a safety issue on a
particular treatment arm.
Chapter 4
Comparing Multi-arm Multi-stage
(MAMS) Group Sequential and P-Value
Combination Adaptive Designs
4.1 Introduction
Two-arm group sequential designs which compare a single treatment arm against
a control arm are well established and frequently adopted for phase 2 and phase 3
clinical trials. These designs are characterized by interim looks at accumulating data
in order to stop the trial early for overwhelming efficacy or futility. Such designs
have been available for at least forty years. Adaptive group sequential designs in
which multiple treatment arms are compared in pairwise fashion to a common control
arm and which permit mid-course corrections such as increasing the sample size or
dropping ineffective treatments, have been available for the past fifteen years and are
only now being adopted in pivotal clinical trials. The statistical methodology for such
designs is of two types. In Chapter 2 and Chapter 3 we discussed a Group Sequential
approach to design this type of trial.
The second approach, referred to here as the MAMS P-value Combination ap-
proach, combines independent p-values from the different stages of the trial in accor-
dance with a prespecified combination function and utilizes closed testing (Marcus
et al. (1976)) to ensure strong control the family wise error rate (FWER). Bauer &
Ko¨hne (1994) first introduced this idea for two-stage designs. At the end of stage 1
52
53
one may examine the accumulated data and select a subset of the initial set of treat-
ments for further testing at stage 2, possibly with a re-estimated sample size. Posch
et al. (2005), introduced a larger family of multiplicity adjusted p-values for the two
stages, proposed the inverse normal combination function for combining them, and
discussed parameter estimation at the end of the trial. Koenig et al. (2008) proposed
an adaptive Dunnett test which combines the closed testing principle of (Marcus et
al., 1976) and the conditional error rate principle of Mu¨ller & Scha¨fer (2001). In this
approach the incremental stage 2 Dunnett p-value is compared to the conditional er-
ror function evaluated at stage 1. Friede & Stallard (2008) showed by simulation that
the adaptive Dunnett test and P-value Combination test that combines the Dunnett
p-values from the two stages have similar operating characteristics.
Main objective of this chapter is to compare the operating characteristics of the
MAMS Group Sequential design and the MAMS P-value Combination design both
analytically and empirically. We shall see that the MAMS Group Sequential ap-
proach dominates the MAMS P-value Combination approach with respect to power.
Hereafter, unless required by the context, we will drop the prefix “MAMS” and will
refer to the two types of designs simply as the Group Sequential design or P-value
Combination design.
In Section 4.2 we introduce the multi-arm two-stage design as we had discussed
in Chapter 3. The notation will be similar to the one used in previous two chapters.
The interim analysis can be used to stop the trial for overwhelming efficacy. In the
event we failed to stop at interim, we incorporate adaptive treatment selection and
sample size re-estimation into the design. In Section 4.4 we compare the power of the
Group Sequential and P-value Combination approaches analytically for the special
case of a two-stage design with no early stopping and no adaptation. A more general
simulation-based comparison that incorporates, treatment selection, early stopping
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and sample size re-estimation at stage 1 is presented in Section 4.5 using a recently
completed cardiovascular trial. We end with some concluding remarks in Section 4.6.
Although we are confining the discussion to designs with two stages, this is for ease
of exposition only. The methods presented here extend directly to more than two
stages.
4.2 Multiple Arms Two Stage Design and Notation
We consider a trial in which D treatment arms indexed by i = 1, 2, . . .D are being
assessed against a common control arm indexed by i = 0. Patients are randomized
between the control or one of the treatment arms, i, in accordance with some prespec-
ified allocation ratio of λi. Response of patients on arm i, i = 0, 1, 2, . . .D, follows a
normal distribution with mean µi and variance σ
2
i . Suppose δi = µi − µ0 represents
the treatment effect of arm i for i = 1, 2, . . .D. Likewise in the previous chapter we
consider a two stage design, indexed by j, where j = 1 stands for the interim look
and j = 2 is the final look. The null hypothesis for treatment arm i is H i0 : δi = 0
and the global null hypothesis is denoted by H0 : δi = 0 for all i = 1, 2, . . .D. We
will test H0 against the alternative H1 : δi > 0 for at least one i. On the similar
line to the previous chapters of this thesis we will use the first subscript to stand
for arm and the second subscript for stage. Score statistics for treatment arm i at
stage j will be represented by Wij =
(
X¯ij − X¯0j
) Iij where X¯ij is the sample mean
of arm i, i = 0, 1, 2, . . .D, based on all data up to and including stage j. Also Iij
is the Fisher information about δi at stage j. Then Iij = n0jΛi, where n0j is the
cumulative number of patients on the control arm up to and including stage j and
Λi =
(
σ20 +
σ2i
λi
)−1
. We know the score statistic W j = (W1j,W2j , ...WDj) at stage j is
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a multivariate Brownian process with following properties:
E(Wij) = δiIij
V ar(Wij) = Iij
Cov(Wi1,Wi2) = Ii1
Cov(Wi1j,Wi2j) = Λi1Λi2σ
2
0n0j ; if i1 6= i2.
We have also seen W 1 and W (2) ≡ (W1(2),W2(2), · · ·WD(2)) = W 2 −W 1 are indepen-
dent and W (2) also follows a multivariate normal distribution with:
E(Wi(2)) = δiIi(2)
V ar(Wi(2)) = Ii(2)
Cov(Wi1(2),Wi2(2)) = Λi1Λi2σ
2
0n0(2); if i1 6= i2.
Here n0(2) = n02 − n01 and Ii(2) = n0(2)Λi is the Fisher information about δi based
on the incremental data between first and second stages. Let δ = (δ1, δ2, ...δD) and
max{W j} = maxi(Wij ; i = 1, 2, ...D) represent maximum score statistic by stage j.
Suppose out of a total type I error α, we are allowed to spend only α1 at the interim.
Under the group sequential approach explained in Chapter 2 and Chapter 3 group
sequential boundaries b1, b2 of a two look level α test should satisfy the following
criteria:
P0 (max{W 1} ≥ b1) = α1
P0 (max{W 1} < b1 ∩max{W 2} ≥ b2) = α− α1, (4.2.1)
where Ph(.) denotes the probability under δ = h. The MAMS P-value Combina-
tion approach, combines independent p-values from the different stages of the trial
in accordance with a prespecified combination function and utilizes closed testing
56
(Marcus et al. (1976)) to ensure strong control the family wise error rate (FWER).
This is discussed next.
4.3 P-value Combination Design
The p-value combination test in the context of adaptive design was first proposed
by Bauer & Ko¨hne (1994). Their method assessed multiple treatment arms against
a common control in a two-stage design. Posch et al. (2005) extended this idea
to an adaptive combination test which allows early stopping due to efficacy along
with the treatment selection feature. They used a combination function to combine
stagewise p-values and applied the closed testing principle to control FWER in strong
sense. Many choices of combination functions are available in the literature. Among
them we mention the Fisher combination function (Bauer & Ko¨hne (1994) ) and
the weighted inverse normal (Lehmacher & Wassmer (1999)) combination function.
Fisher’s combination function is the product of independent p-values from the two
stages. The weighted inverse normal combination function combines independent
p-values p1, p2 from the two stages as
C(p1, p2) = 1− Φ(h1Zp1 + h2Zp2). (4.3.2)
Here Φ denotes the standard normal distribution function and Zα = Φ
−1(1 − α).
The prespecified weights h1, h2 must satisfy h
2
1 + h
2
2 = 1 and h1, h2 ≥ 0. Assuming
n1, n(2) as total sample sizes used in first and second stage, a common choice of
weights are h1 =
√
n1
n1+n(2)
, h2 =
√
n(2)
n1+n(2)
. In the context of a multi-arm multi-
stage design, we are comparing D treatment arms against a common control in a two
stage design. As discussed previously, in order to have strong control of FWER at
level α, we may reject H i0 only if H
I
0 is rejected by a valid local level-α test for all
possible subsets I of D that include i. Any valid multiplicity adjusted p-values may
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be utilized in equation 4.3.2 for the test of HI0 . Popular candidates include the t-test
based p-values, adjusted for multiplicity by the non-parametric Bonferroni and Simes
procedures (see, for example, in Posch et al. (2005)). However, in order to make
a meaningful comparison between the Group Sequential approach and the P-value
Combination approach, we will utilize p-values that are derived from the maximum
score statistic. In that case the multiplicity adjusted p-value for testing HI0 at stage
j is given by
pIj = P0
(
max{W Ij} > max{wI1}
)
. (4.3.3)
For future reference (see Table 4.1) we refer to this p-value as the Dunnett p-value. We
will use the same type-1 error, α1, for the first stage as was used in Group Sequential
approach. This will make both methods comparable in terms of early stopping. The
trial can be stopped at the interim look if pI1 < α1 for all possible subsets I of D
such that i ∈ D .
The trial terminates if at least one H i0 is rejected at the interim look. Otherwise,
treatment selection may occur. Accordingly let S be the set of treatment indexes
selected for second stage and IS = I ∩ S be the set of treatments from I that are
carried forward to stage 2. Suppose max{W IS(2)} = max(Wq(2); q ∈ IS) represents
the maximum incremental score statistic corresponding to the set IS and max{wIS(2)}
is its observed. Then the second stage p-value for testing HI0 is
pI(2) = P0(max{W IS(2)} > max{wIS(2)}). (4.3.4)
Let h1, h2 be the weights from the two stages. Using the inverse normal combination
function we will reject HI0 at the final analysis if
C(pI1, pI(2)) = 1− Φ(h1ZpI1 + h2ZpI(2)) < c. (4.3.5)
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The final stage c solves the following equation -
1∫
α1
1∫
0
1[C(x,y)≤c]dydx = α− α1.
The indicator function 1[.] takes value 1 when C(x, y) ≤ c and 0 otherwise. We can
reject Hs0 with strong control of FWER if C(pI1, pI(2)) ≤ c. for all possible subsets I
of D with s ∈ I.
4.4 Group Sequential versus P-value Combination
Our goal is to compare the Group Sequential and P-value Combination approaches
with respect to global power, defined here as the probability of rejecting H i0 for any
treatment i, i = 1, 2, . . .D. We wish to perform analytical comparisons so as to gain a
deeper insight into the conditions under which one method has greater power than the
other. In order to obtain analytical formulae we make some simplifying assumptions.
We compare only two treatment arms (D = 2) against a common control arm in a
two stage design. Patients are randomized equally to the three arms of the study and
each patient’s response is normally distributed with σ2 = 1. The control arm has a
mean of zero and treatment i has mean δi, i = 1, 2. The null hypothesis corresponding
to the treatment i is H i0 : δi = 0. We will test the global null hypothesis H0 : δi = 0
for i = 1, 2 against the alternative H1 : δi > 0 for any i = 1, 2 . The score statistic
W j, for j = 1, 2 will be used to make test decisions. There will be no early stopping
for efficacy, no dropping of treatments and no adaptive sample size re-estimation.
The sole objective is to compare the powers of the Group Sequential and P-value
Combination approaches analytically and thereby identify conditions under which
one method dominates the other.
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4.4.1 Analytical Power for the Group Sequential Design
First we will derive the formula for computing power using the Group Sequential ap-
proach. Here, power is defined as probability of rejecting H0 when the true treatment
effect is δ = (δ1, δ2). We will denote this probability by P (GSD) . Since there is no
early stopping, the first stage boundary b1 is ∞. Assuming b2 as the second stage
boundary, P (GSD) can be computed as:
P (GSD) = Pδ (max{W12,W22} ≥ b2)
=
∞∫
−∞
∞∫
−∞
Pδ (max{W12,W22} ≥ b2|W1 = (w11, w21)) f1(w11, w21)dw11dw21
= 1−
∞∫
−∞
∞∫
−∞
Pδ (max{W12,W22} < b2|W1 = (w11, w21)) f1(w11, w21)dw11dw21
= 1−
∞∫
−∞
∞∫
−∞
Pδ
(
W1(2) < b2 − w11 ∩W2(2) < b2 − w21
)
f1(w11, w21)dw11dw21
= 1−
∞∫
w21=−∞
∞∫
w11=−∞


b2−w21∫
w2(2)=−∞
b2−w11∫
w1(2)=−∞
f(2)(w1(2), w2(2))dw1(2)dw2(2)


f1(w11, w21)dw11dw21 (4.4.6)
4.4.2 Analytical Power for the P-Value Combination Design
Computing power using the p-value combination approach requires the evaluation
of incremental p-values from the two stages. The p-value, p1, for testing H0 at the
interim analysis utilizes data from first stage. Let w1 = (w11, w21) be the observed
score statistic at the interim look. Then
p1 = P0 (max{W11,W21} ≥ max(w1) = max(w11, w21))
= 1− P0 (W11 < max(w1) ∩W21 < max(w1)) .
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The second stage p-value, p(2), is computed from the data obtained after the interim
analysis. Let w(2) = (w1(2), w2(2)) be the corresponding score statistic based on the
incremental data from the second stage. Then
p(2) = P0
(
max{W1(2),W2(2)} ≥ max(w(2)) = max(w1(2), w2(2))
)
= 1− P0
(
W1(2)} < max(w(2)) ∩W2(2) < max(w(2))
)
.
We will use the inverse-normal combination function and h1, h2 as weights from the
two stages. Since there is no early stopping the second stage boundary c is equal to
Zα. So, the rejection criteria for H0 under p-value combination test approach is
h1Zp1 + h2Zp(2) ≥ Zα.
Here we will denote this probability of rejecting H0 by P (Comb) and this can be
computed as:
P (Comb) = Pδ
(
h1Zp1 + h2Zp(2) ≥ Zα
)
=
∞∫
−∞
∞∫
−∞
Pδ
(
Zp(2) ≥
Zα − h1Zp1
h2
|W 1 = w1
)
f1(w11, w21)dw11dw21
=
∞∫
−∞
∞∫
−∞
Pδ
(
p(2) ≤ 1− Φ
(
Zα − h1Zp1
h2
))
f1(w11, w21)dw11dw21.
Here f1(w11, w21) is the probability density function of (W11,W21). It follows a mul-
tivariate normal density given in Section 3.2. In the above equation Zp1 is a function
of both w11 and w21. Suppose max(w(2)) = max(w1(2), w2(2)) is the maximum ob-
served score statistic from the second stage. Then we can write the second stage
p-value as p(2) = P0(W1(2) ≥ max(w(2)) ∪ W2(2) ≥ max(w(2))) = 1 − P0(W1(2) <
max(w(2)) ∪ W2(2) < max(w(2))) = 1 − F(2)(max(w(2))). Here F(2)(x) is a univari-
ate function, that represents the probability that both W1(2) and W2(2) are less than
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x when H0 is true. Let f(2)(w1(2), w2(2)) denote the probability density function of
(W1(2),W2(2)), which is also a multivariate normal density. With this notation we can
write the P (Comb) as:
P (Comb) =
∞∫
−∞
∞∫
−∞
Pδ
(
1− F(2)(wmax(2) ) ≤ 1− Φ
(
Zα − h1Zp1
h2
))
f1(w11, w21)dw11dw21
=
∞∫
−∞
∞∫
−∞
Pδ
(
F(2)(w
max
(2) ) ≥ Φ
(
Zα − h1Zp1
h2
))
f1(w11, w21)dw11dw21
=
∞∫
−∞
∞∫
−∞
Pδ
(
wmax(2) ≥ F−1(2) (g)
)
f1(w11, w21)dw11dw21
= 1−
∞∫
w2(2)=−∞
∞∫
w1(2)=−∞


F−1
(2)
(g)∫
w2(2)=−∞
F−1
(2)
(g)∫
w1(2)=−∞
f(2)
(
w1(2), w2(2)
)
dw1(2)dw2(2)


f1(w11, w21)dw11dw21, (4.4.7)
where g = Φ
(
Zα−h1Zp1
h2
)
is a function of w11, w21.
4.4.3 Comparison of Analytical Results
In equations 4.4.6 and 4.4.7, we are integrating the probability density functions of
(W11,W21) and (W1(2),W2(2)). The integrands are the same in both the equations,
but the region of integration differ between these two equations. This can be seen
by examining the limits of integrals. We compare the powers of two approaches in
Figure 4·1. The three graphs in the three columns of Figure 4·1 represent δ1 =
0, 0.2, 0.4 respectively. The x-axis shows δ2 varying from 0 to 0.4 . We have used a
total sample size of 300 (100 on each arm) and total type I error as 0.025 in both
the approaches. Figure 4·1 shows that the Group Sequential approach dominates the
P-value Combination approach. The two approaches produce same power, when both
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Figure 4·1: Power comparisons between the Group Sequential and
P-value Combination approaches
the treatments have similar effects. But when one treatment is more effective than
the other, the Group Sequential approach produces more power than the P-value
Combination approach. For example, when one treatment is completely ineffective
(δ1 = 0) but the other treatment has a large effect (δ2 = 0.4), 5% more power is
realized with the Group Sequential approach. The study (global) power is defined as
the probability of rejecting at least one of H10 or H
2
0 .
When H0 is rejected by the Group Sequential method it is because W
max
2 has
crossed an efficacy boundary. That is, either W12 or W22 or both have crossed the
efficacy boundary. Thus we can automatically also reject either H10 or H
2
0 , or both
of them, depending on which component(s) of W2 crossed the efficacy boundary.
For the P-value combination test, however, rejecting H0 does provide any additional
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information about the status of H10 , H
2
0 . Therefore we need to further reject either H
1
0
orH20 or both by local level-α tests before we an make an efficacy claim for one or more
dose groups. These additional tests have not been factored into the analytical power
calculations for the P-value Combination approach. Therefore we can conclude that
the actual power of the P-value Combination approach to identify efficacious doses is
even less than P (Comb) which in turn is dominated by P (GSD). Thus the Group
Sequential approach always perform better than the P-value Combination approach
in terms of study power.
The analytical expressions in (4.4.7) and (4.4.6) were derived in the idealized
setting of no early stopping and no dropping of treatment arms at the end of stage 1.
In the next section we will simulate these two approaches in the more realistic setting
of an actual two-stage clinical trial with possible early stopping boundary, treatment
selection and sample size re-estimation at the interim look.
4.5 The SOCRATES-REDUCED Trial
SOCRATES-REDUCED was a multi-center, randomized, placebo-controlled trial
which enrolled patients with worsening chronic heart failure after clinical stabilization
( Gheorghiade et al. (2015) ). Patients were randomized to three different dose groups
(2.5, 5, 10 mg) of oral vericiguat or placebo. The primary end point of the trial was
change from baseline to week 12 in log-transformed level of N-terminal pro-B-type
natriuretic peptide (NT-proBNP). The statistical analysis plan specified that for the
analysis of the primary endpoint the patients from the three dose groups would be
pooled and compared to the placebo arm. The trial was designed for 80% power
to detect a difference of δ = 0.187 between the pooled dose group and placebo, at
1-sided α = 0.025. In order to meet these design requirements, and assuming that
σ = 0.052, a total of 260 patients (65/arm) were randomized to the study. This trial,
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however, failed to show statistical significance. The observed treatment effect for the
pooled dose group relative to placebo was only 0.122 (p-value = 0.075, 1-sided).
The data from the trial showed a dose-response relationship with an observed
difference from placebo of 0.248 for the 10 mg dose group (p = 0.024), 0.073 for the
5 mg dose group (p = 0.15), and 0.04 for the 2.5 mg dose group (p=0.19). It was a
mistake to prespecify that the primary efficacy analysis should be based on pooling the
three dose groups since a dose-response relationship was to be expected, and pooling
would dilute the response observed for the best dose. An alternative design in which
the primary efficacy analysis consisted of separate pairwise comparisons between each
dose and the common placebo arm with 80% power to detect a difference of δ = 0.187
would have been preferable. In this section we will consider such a design and obtain
its operating characteristics under different assumptions concerning the treatment
effect.
A single look four arm design based on Dunnett’s test in which σ = 0.52 and
δ = 0.187 for each dose versus placebo requires 388 patients (97/arm) for 80% power
at 1-sided α = 0.025. Here power is defined as the probability that the null hypothesis
δ = 0 will be rejected for at least one dose group. In Table 4.1 we compare the operat-
ing characteristics of this single-look design with corresponding operating character-
istics of P-value Combination designs that utilize three different multiplicity adjusted
p-values (Bonferroni, Simes or Dunnett), and a Group Sequential design, under a
range of treatment differences from placebo for the three dose groups. All designs are
conducted over two stages with treatment selection and sample size adaptation at the
end of stage 1. The adaptation consists of early stopping if any dose group crosses the
efficacy boundary, or dropping any dose group having an observed treatment effect
that is worse than placebo. When doses are dropped their stage 2 sample sizes are re-
allocated in equal proportion to the remaining doses or placebo. The Bonferroni and
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Simes two-stage procedures combine p-values derived from the student-t distribution.
The multiplicity adjusted Dunnett p-values are derived by equation (4.3.3). All table
entries are based on 10,000 simulated trials. All the designs have a planned sample
size of 388 patients with an interim analyses after 194 patients, and possible early
stopping or treatment selection. The value of αj that is spent at stage j, j = 1, 2, is
derived from the Lan and DeMets error spending function. For the Group Sequential
design, the boundaries bj , j = 1, 2, can be derived as shown in equation (4.2.1). How-
ever, we have a similar correction to these boundaries as discussed in Section 3.4.1
in Chapter 3. The last row of Table 4.1 shows that this adjustment preserves the
type-1 error despite the small number of patients enrolled on each treatment arm at
each stage. Consistent with the analytical comparisons in Section 4.4.3, the adaptive
Table 4.1: Power Comparison for SOCRATES-REDUCED, using
Multiple Arm designs
Power (%)
Adaptive P-value Combination Adaptive
Single Group
δ Look Bonferroni Simes Dunnett Sequential
(0.04, 0.073, 0.25) 84.1 80.7 82.5 86.1 88.9
(0.187, 0.187, 0.187) 80.4 73.6 79.3 80.1 80.97
(0, 0.187, 0.187) 73.1 67.8 71.2 76.8 78.85
(0, 0.094, 0.187) 57.1 50.9 55.2 61.3 64.86
(0, 0, 0.187) 59.1 52.1 54.0 62.7 64.66
(0, 0, 0) 2.502 1.52 2.01 2.53 2.418
Group Sequential design dominates the P-value Combination designs. Furthermore
among the three P-value Combination methods displayed in Table 4.1, the Bonfer-
roni and Simes methods have considerably lower power than the Dunnett’s method.
When the three dose groups have similar treatment effects the power obtained by
the P-value Combination design using Dunnett’s method has about the same power
as the adaptive Group Sequential design. On the other hand, when the treatment
effects are heterogeneous, the adaptive Group Sequential design has greater power
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than the P-value Combination designs. For example when δ = (0.187, 0.187, 0.187)
both methods produce power of 80%. But if δ = (0, 0.187, 0.187), the adaptive Group
Sequential design produces 1.5% more power than the P-value Combination design
with Dunnett’s p-values, and if δ = (0, 0, 0.187), the adaptive Group Sequential de-
sign produces 3% more power than the P-value Combination design using Dunnett’s
p-values. When we simulated under the treatment effect actually observed in the
SOCRATES-REDUCED trial, δ = (0.04, 0.073, 0.25), the adaptive Group Sequential
design had 2.5% greater power than the P-value Combination design using Dunnett’s
p-values. The single look MAMS design produced power comparable to that of the
adaptive P-value Combination design with Dunnet’s p-values and the adaptive Group
Sequential design when all the dose groups had a similar effect. In all other cases it
produced lower power.
4.6 Discussion
The usual practice in clinical drug development has been to first run a phase 2 trial
with multiple doses, and then run a separate two-arm phase 3 trial in which the best
dose from phase 2 is compared to a control arm. Adaptive MAMS designs combine
phase 2 and phase 3 into a single integrated trial and thereby utilize fewer patient
resources and shorten the time to identify and market efficacious medical products.
To be acceptable for regulatory submissions such designs must have strong control
of FWER. Both the P-value Combination and Group Sequential designs have his
property. The P-value Combination methods originated in the late 1990’s from the
seminal work of Bauer & Ko¨hne (1994). The earliest MAMS group sequential design
was generalization of two-arm group sequential design, based on the distribution of the
maximum Wald statistic amongst the dose groups, was proposed by Stallard & Todd
(2003). There have been many subsequent advances for both methods. The current
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work is, however, the first time the two methods have been compared analytically as
per our knowledge.
We have shown that the Group Sequential method has greater power than the
P-value Combination method, both analytically and in a simulation experiment in-
volving a published trial. There are two reasons for the greater efficiency. First, the
test statisticW j utilized by the Groups Sequential approach is a sufficient statistic for
the treatment effect δ, unlike the test statistic based on the combination of p-values.
Second, the Group Sequential approach exploits the correlation between W 1 and W 2
whereby W 1 and W 2 −W 1 are independent. This is exactly true for normally dis-
tributed data with known variance and asymptotically true in other situations. On
the other hand the P-value combination method requires only that the p-values for
the two stages should be valid (i.e., have a distribution that is stochastically larger
than uniform) and independent, for then their weighted combination derived from
equation (4.3.2) is also a valid p-value. Since this weighted combination does not
exploit the special structure of the sequentially computed test statistics the P-value
Combination approach is less efficient than the Group Sequential approach. However,
the P-value Combination method is more general in the sense that any choice of valid
p-values for each stage, not just the ones defined by equations (4.3.3) and (4.3.4), can
be combined to yield a valid combination p-value. It is thus less dependent on the
assumption of asymptotic normality.
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Chapter 5
Conclusions
Considering the recent availability of new therapies in many disease areas and the
increasing cost to clinical research, it is evident that efficient designs to identify effec-
tive treatments in the shortest time are essential. A multi-arm multi-stage (MAMS)
design is a great contribution towards this goal. The multi-arm element of this design
will allow several treatments to be assessed simultaneously against a common control
group, within a single randomized trial. The multi-stage element will give the ben-
efit of stopping the trial early based on a series of pre-planned interim analyses by
either one treatment being sufficiently efficacious or all the treatments being futile.
In addition there can be a cost saving due to dropping ineffective arms at interim
analyses time points. In the absence of MAMS design, it is traditional to conduct
separate 2 arm group sequential trials to assess each new treatment against its own
control. This is an inefficient and inadequate approach for keeping pace with drug
discovery due the fact that each trial requires a separate control arm and there is
little to no opportunity to stop all the trials prematurely if any experimental arm is
showing an overwhelming benefit. Therefore use of such traditional designs increases
the cost and time of drug development and restricts the number of treatments that
can be tested at a time. However, till today, this is the approach that is commonly
used in practice perhaps due to its simplicity. An alternate approach was tried in
the SOCRATES-REDUCED trial (Gheorghiade et al. (2015)) where three treatment
arms were pooled and the pooled treatment group was compared against the placebo
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using a two-arm design. The trial failed to prove that the pooled treatment group is
efficacious. However, exploratory analysis of the data revealed that the best treat-
ment demonstrated sufficient efficacy while the other two treatments were poor. In
retrospect the trial could have succeeded had an adaptive MAMS design been used.
As a consequence there has been growing interest in designing multi-arm multi-
stage (MAMS) designs. While the interest is evident, it should be noted that only
a few confirmatory trials have taken place using this type of design. If we were to
take a closer look at clinical trials using MAMS design, one thing stands out that
the statistical methodology employed has been, by default, the P-value Combination
approach. This method is attractive due to its simplicity and great flexibility. It
computes independent multiplicity adjusted p-values from each stage and combines
them using some prespecified combination function. Its flexibility rests on the fact
that it does not make any assumption about the underlying distribution of patients
response and any type of multiplicity adjustment (such as Bonferroni, Simes, Dun-
nett) can be used. But there has been discussion in the literature (see Jennison &
Turnbull (2006) and Tsiatis & Mehta (2003)) that P-value Combination approach is
inferior when compared to Group Sequential approach in two-arm settings. One of
the criticisms is that the P-value Combination design suffers by ignoring correlations
between cumulative data from successive stages.
Adopting the Group Sequential approach in MAMS design runs into computa-
tional difficulties. Analytical computation of the group sequential boundaries requires
a multi-dimensional integration where the dimension equals to the product of num-
ber of comparison arms and number of stages. If proper care is not been taken this
explodes when number of stages is more than than three or four. Previous attempts
to solve this problem have met with mixed success.
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5.1 Summary of the thesis
Chapter 2 in this thesis provides a break-through algorithm that can compute MAMS
group sequential boundaries rapidly thereby making such designs practical. This al-
gorithm exploits the independent increments property of score statistics which allows
the computation to grow linearly with the number of stages. Then it makes use of the
Quasi-Monte Carlo method to compute the multivariate normal probability, required
in MAMS Group Sequential design.
As discussed, interim analyses in this design allow early stopping of the trial either
due to efficacy or futility. Additionally, interim analysis can be used to drop arms
that are performing poorly. One can also modify sample size or make other adaptive
changes like modifying patient randomization at one or more interim analyses. There-
fore, we extended our proposed MAMS Group Sequential design to allow adaptive
changes at an interim analysis without inflating the prespecified level of family wise
error rate. This adaptive MAMS Group Sequential design makes use of the condi-
tional error rate principle (Mu¨ller & Scha¨fer (2001)). Also closed testing is necessary
to control FWER in strong sense. This adds more flexibility in terms of designing a
MAMS trial.
An alternative method to design MAMS trials is the P-value Combination de-
sign (Posch et al. (2005)). This design is commonly used in seamless phase II/III
trials, which involves adaptive treatment selection at end of phase II and only se-
lected treatments from phase II will be tested in phase III. To make a meaningful
comparison between these two approaches we utilized p-values computed from the
same statistic as in Group Sequential approach. We then compared the statistical
powers obtained from these MAMS Group Sequential approach and P-value Combina-
tion approach analytically in the absence of any adaptive changes. When treatment
effects were heterogeneous in nature MAMS Group Sequential approach produced
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almost 5% more power than the P-value Combination approach. Simulations were
used to compare powers in the presence of adaptive changes at the interim. Again
the MAMS Group Sequential approach had superior operating characteristics to that
P-value Combination approach in the presence of heterogeneity. We used the example
from a recently conducted cardiovascular trial to compare three treatments against
a placebo. We concluded that the MAMS Group Sequential design dominates the
P-value Combination design.
5.2 Future Research Ideas
The formulation proposed in Chapter 2 uses the underlying normal distribution of
the response. Section 2.2.2 in Chapter 2 goes some way towards making the MAMS
design applicable to other endpoints like binary, time-to-event and even to regression
models. However, further work is needed to allow any type of mixed endpoints (e.g.
a binary intermediate at the interim and a continuous definitive endpoints at the
end) to be used in a MAMS trial. Work done by Jaki & Magirr (2013) will be good
reference towards this issue.
In case of normally distributed endpoint, a common assumption is made at the
design stage about the variance of the responses. Although we assume the variance
to be a known quantity but it may not be the case in reality. Even if a prior estimate
of the variance is available, it is usually subject to considerable uncertainty. Use
of a test statistic that assumes a known variance will lead to incorrect conclusion
if the actual variance differs from the quantity assumed at the design stage. Shao
& Feng (2007) had suggested to use Monte Carlo simulation to modify the two-arm
group sequential boundaries computed assuming known variance. Our simulation
experiment in Section 4.5 from Chapter 4 used a correction to the boundaries as
suggested by Wason et al. (2016) and FWER was controlled there. But modifying
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the stopping boundaries is not sufficient to control both the FWER and power at
the same time if the variance in the real trial changes from the design value. In
confirmatory trials, the priority should be placed on controlling the FWER and the
adjustment suggested by Wason et al. (2016) may solve the problem. More research
is needed if one wishes to control both FWER and power simultaneously. But an
exact solution for unknown variance can be obtained under the P-value Combination
methodology (see Wassmer (2011)).
Much discussion has recently been made over adding arms to an ongoing MAMS
design. For example the STAMPEDE trial (Sydes et al. (2009)) has added a fur-
ther treatment arm due to excellent recruitment rates after the trial started. When
controlling the FWER is of interest, adding a new treatments is in general not ad-
visable. This will increase the FWER and can also alter the study power. The main
research question to this problem will be how to adjust the future stage boundaries
by controlling overall FWER.
5.3 Conclusion
The multi-arm multi-stage design has demonstrated its ability to accelerate the drug
development process in oncology and could have a similar impact in other disease ar-
eas. The work done in this thesis allows efficient computation of the group sequential
boundaries using the breakthrough algorithm explained in Chapter 2, so as to make
the use of these designs practical for researchers. This is extended to allow adaptive
changes like treatment selection, sample size modification all the while maintaining
a strong control over FWER. With this efficient algorithm several design scenarios
using this approach can be compared in real time and thereby giving the researchers
the option to choose the best one for their purpose. P-value Combination design is the
alternative approach to this problem and our work found MAMS Group Sequential
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design have advantage over P-value Combination design in terms of statistical power.
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Appendix A
Supplementary Materials : ”Repeated
evaluation of Component Probabilities in
MAMS Group Sequential Design”
We first show how equations (2.2.3) through (2.2.6) can be solved by repeated eval-
uation of “component probabilities” of the form (2.2.7) where cj is either aj or bj
depending on the context. To see this observe that equation (2.2.3) can be written as
P~0(
⋂j−1
l=1 max{ ~Wl} < bl ∩max{ ~Wj} ≥ bj) = αj
⇒ P~0(
⋂j−1
l=1 max{ ~Wl} < bl)− P~0(
⋂j−1
l=1 max{ ~Wl} < bl ∩max{ ~Wj} < bj) = αj
⇒ 1−∑j−1k=1 αk − P~0(⋂j−1l=1 max{ ~Wl} < bl ∩max{ ~Wj} < bj) = αj
⇒ P~0(
⋂j
l=1max{ ~Wl} < bl) = 1−
∑j
k=1 αk
Next observe that the left hand side of (2.2.6) can be written as
P~δ1(
j−1⋂
l=1
al < max{ ~Wl} < bl ∩max{ ~Wj} ≤ aj)
=
∑
c1∈{a1,b1}
· · ·
∑
cj−1∈{aj−1,bj−1}
sign(c1) · · · sign(cj−1)P~δ1
j−1⋂
l=1
max{ ~Wl} < cl ∩max{ ~Wj} < aj)
where sign(cj) = 1 if cj an efficacy boundary and -1 otherwise. To compute this
probability we need to evaluate 2j terms of the form (2.2.7).
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Appendix B
Supplementary Materials :
”Transformation of the Probability Limits
in MAMS Group Sequential Probability
Computation”
We derive the upper limits of integration, gil, i = 1, 2, . . .D, l = 1, 2, . . . J , in equation
(2.4.16). From the transformation (~u(l) − t(l)~η)/
√
tl = C~yl we have
ui(l) = t(l)ηi +
√
t(l)
i∑
m=1
Cimyml
Then
ui(l) < dl − ui,l−1
⇒t(l)ηi +
√
t(l)
i∑
m=1
Cimyml < dl −
l−1∑
k=1
t(k)ηi −
l−1∑
k=1
√
t(k)
i∑
m=1
Cimymk
⇒√t(l)Ciiyil +√t(l) i−1∑
m=1
Cimyml < dl −
l∑
k=1
t(k)ηi −
i∑
m=1
Cim
l−1∑
k=1
√
t(k)ymk
⇒√t(l)Ciiyil < 1
Cii
[
1√
t(l)
(
dl − t(l)ηi −
i∑
m=1
Cim
l−1∑
k=1
√
t(k)ymk
)
−
i−1∑
m=1
Cimyml
]
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Appendix C
Supplementary Materials : Lattice
Parameters for QMC Algorithm
Figure C·1: Subset of (P, vP ) points utilized for QMC
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